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 Five-membered heterocycles represent a privileged scaffold in drug discovery and are the 
focus of analog design. The first chapter presents the synthesis and biological evaluation of 
analogs of NSC 652287, which targets the renal carcinoma cell line A498. The Pd-catalyzed 
Suzuki-Miyaura cross-coupling with halogenated furan, thiophene, and selenophene led to 
generally high overall yields for the construction of heterocyclic triads. C-H bond activation 
provided an efficient strategy for the Pd-catalyzed cross-coupling at C(2) of oxazoles. Further 
analog variation was achieved with a copper-catalyzed azide-alkyne cycloaddition to form a 1,4-
substituted 1,2,3-triazole. Potency and selectivity of the final hydroxymethyl products were 
determined in the NCI-60 cell assay. Two lead compounds were tested in vivo and compared to 
NSC 652287. The evaluation of these compounds continues with a thermal shift assay coupled 
with differential mass spectrometry for biological target identification. The chemical stability of 
select triads are also discussed. 
The second chapter details the synthesis of thienopyridone and thienopyrimidine dione 
analogs as inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3), an attractive anticancer 
target. Derivatization by photooxygenation led to a compound with a unique structural motif, 
high potency, and excellent selectivity towards PTP4A3. An automated synthesis strategy using 
Lilly’s Automated Synthesis Lab was employed for analog synthesis. 
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1.0 HETEROCYCLIC TRIADS AS POTENTIAL CHEMOTHERAPEUTICS 
TARGETING RENAL CELL CARCINOMA 
1.1 INTRODUCTION 
1.1.1 Renal Cell Carcinoma and Therapeutic Challenges 
 Kidney and renal pelvis cancer will account for nearly 64,000 new cases and >14,000 
deaths in the United States in 2017.1 Renal cell carcinoma (RCC) encompasses a variety of 
highly vascularized heterogeneous solid tumors, creating a dependence on angiogenesis for 
tumor growth and progression.2 Significant advances in the understanding of RCC biology led to 
the development of therapeutic agents targeting the von Hippel-Lindau (VHL)/hypoxia-inducible 
factor (HIF)/vascular endothelial growth factor (VEGF) pathway (Figure 1).2-3 This pathway is a 
cellular response mechanism for low concentrations of molecular oxygen, O2, also known as 
hypoxia.  
 Under normal O2 concentrations, HIF is enzymatically hydroxylated on a proline residue 
by an O2 dependent process. The hydroxyl group retards aggregation of HIF, which prevents its 
transcriptional role and enables higher recognition and binding affinity by VHL, an E3 ligase, 
which signals HIF for ubiquitination and proteasome mediated degradation. When hypoxia 
occurs, HIF is not hydroxylated/inactivated but aggregates into the active form leading to the 
2 
transcriptional activation of HIF target genes. The new proteins then target VEGFR and platelet-
derived growth factor receptors (PDGFR), resulting in angiogenesis. To mimic this hypoxia 
response under normal O2 concentrations, clear cell RCC typically has mutated or epigenetically 
inactivated VHL where HIF is no longer regulated, and thus leads to angiogenesis and tumor 
growth.4 An alternate route to angiogenesis proceeds through the PI3K/Akt signaling pathway, 
which activates the mammalian target of rapamycin (mTOR). In addition to overlapping with the 
HIF pathway, the activation of mTOR leads to the production of Cyclin D1 and c-Myc, resulting 
in cancer cell growth and survival.3b 
 
Figure 1. Illustration of the VHL/HIF/VEGF pathway. The red boxes indicate targets of FDA 
approved therapeutic agents.3b Reprinted with permission. © 2009 American Society of Clinical 
Oncology. All rights reserved.  
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There are a number of United States Food and Drug Administration (FDA) approved 
therapeutic agents that act on the VHL/HIF/VEGF pathway and mTOR (Figures 1 and 2).2-4 The 
macrolides everolimus and temsirolimus share the same core as the natural product rapamycin 
and inhibit mTOR via hydrophobic interactions at the three conjugated π-bonds, preventing 
tumor proliferation.5 Both macrolides also interact with the prolyl isomerase FK506 binding 
protein (FKBP), with the piperidine ring acting as a proline mimic. Bevacizumab is an anti-
VGEF monoclonal antibody that is co-administered with interferon α.2-4 The small molecules 
axitinib, cabozantinib, lenvatinib, pazopanib, sorafenib, and sunitinib are potent and selective 
protein tyrosine kinase inhibitors of growth factor receptors, including VEGFR and PDGFR.2-4,6 
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Figure 2. Chemical structures of therapeutic agents approved for kidney cancer treatment.6 
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Current therapeutics can provide patients with some initial relief as first or second 
treatment options, but positive response is often not sustained which results in relapse and 
eventual patient death from either RCC or drug induced toxicity.2-4,7 Patients with advanced RCC 
have a 5-year survival rate of about 6%.2,4 In many cases, tumor cells develop resistance to the 
kinase inhibitors through either inherent mechanisms such as low drug uptake, or acquired 
mechanisms such as activation of alternate pathways for tumor proliferation.4 Combination 
therapies of the kinase and mTOR inhibitors have been attempted, but often led to unacceptable 
toxicity.3c Further optimization of these kinase inhibitors may not lead to more successful and 
safe therapies, especially with the high potency of current drugs. For example, axitinib is 50-450 
times more potent than sunitinib, sorafenib, and pazopanib with subnanomolar IC50 values and 
better specificity, but it presents adverse effects similar to other treatment options.2,8 Thus, 
discovery of antitumor molecules that involve mechanisms of action outside of the 
VHL/HIF/VEGF pathway would be clinically useful.  
1.1.2 Heterocyclic Triads as Potent Inhibitors of Renal Carcinoma Cell Line A498 
 A common approach for drug discovery is the utilization of phenotypic screening to 
identify lead candidates before developing target oriented analog designs.9 The National Cancer 
Institute (NCI) Anticancer Drug Screen was established in the late 1980s as an initiative for 
anticancer drug discovery.10 This phenotypic screen, also known as NCI-60, consists of 60 well 
characterized tumor cell lines representing leukemia, non small-cell lung, colon, central nervous 
system, melanoma, ovarian, renal, prostate, and breast cancers. Approximately 2,500 compounds 
solicited from government, industrial, and academic labs are tested every year as part of a 
disease-oriented preclinical screening with about 2% of the screened compounds progressing to 
5 
mice studies. Testing is conducted with a 1- or 5-concentration colorimetric assay, most 
commonly utilizing sulphorhodamine B as the protein dye.10-11 The NCI then utilizes a computer 
algorithm (COMPARE), which identifies similarities in the activity of screened compounds to 
well-known standards, in an effort to predict likely cellular targets and mechanisms of action.12 
The bioactivity profiles generated from the NCI-60 assay have enabled the elucidation of the 
mechanism of action of several compounds such as halichondrin B, a natural product that targets 
tubulin for mitotic inhibition and led to the FDA-approved analog eribulin for the treatment of 
breast cancer, and bortezomib, a proteasome inhibitor and FDA-approved drug for the treatment 
of myeloma.10,13 Thus, the NCI-60 assay provides a widely accessible screening tool for the 
identification of potential novel therapeutic agents targeting cancers such as RCC.14 
 Among the compounds screened in the NCI-60 assay, Rivera and coworkers, in 1999, 
identified the growth inhibition of renal cell line A498 by a heterocyclic triad known as National 
Service Center (NSC) 652287 (1-1) (Figure 3).15 The α-terheterocycle scaffold in 1-1 may be 
regarded as a structural alert by medicinal chemists due to the potential toxicity that can result 
from chemical reactivity and bioactivation of the electron-rich heterocycles.16 Despite these 
concerns, five-membered heterocycles remain a privileged scaffold in medicine (Figure 3).16b,17 
For example, clopidogrel, a member of the thienopyridine class of antiplatelet agents, is a 
prodrug that requires bioactivation by CYP, which oxidizes the thiophene ring.18 Tiotropium 
bromide, which features two thiophene rings, is a muscarinic receptor antagonist used in the 
management of chronic obstructive pulmonary disease.19 Duloxetine is a serotonin-
norepinephrine reuptake inhibitor that undergoes oxidation on the naphthyl ring rather than the 
thiophene20 and rivaroxaban is an anticoagulant used to prevent blood clots by inhibiting direct 
factor Xa.21 In addition to marketed drugs, naturally occurring and synthetic dithiophenes, 
6 
terthiophenes, and related analogs have been shown to have insecticidal, bactericidal, antifungal, 
antitumoral, and antiviral activity (Figure 3).22 For example, α-terthiophene 1-2 and related alkyl 
substituted terthiophenes are naturally occurring phototoxic sensitizers of plant origin with useful 
insecticidal and bactericidal applications.22a,b Ether-substituted terthiophene 1-3, isolated from 
the plant species Eclipata prostrata, has potent submicromolar antihyperglycemic activity 
against dipeptidyl peptidase IV,22e dialdehyde 1-4 is a potent protein kinase C inhibitor,23 and 
diol 1-5 showed 100-fold higher cytotoxicity against wild-type human colon cancer cell line 
HCT-116 versus its p53 knockdown (HCT-116/p53-/-).22d Additionally, oligothiophenes have 
been considered for use as possible fluorescent markers for biological applications due to their 
extended π-system.24 Accordingly, terthiophenes and related triads provide a versatile scaffold 
with a wide range of bioactivities that are readily modulated by minor structural modifications. 
These observations warrant a more detailed exploration of this heterocyclic triad scaffold as a 
potential therapeutic agent against RCC.  
7 
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Figure 3. Structures of FDA-approved drugs featuring thiophenes, NSC 652287 (1-1), and 
closely related heterocyclic triads. 
1.1.3 Reported Studies on the Mechanism of Action and Metabolism of NSC 652287  
 NSC 652287 (1-1) showed potent activity against a number of cancer cell lines with a 
GI50 value of about 0.02 µM in the renal cancer cell line A498.15 More importantly, 1-1 did not 
impact all the cancer cell lines equally, indicating some selectivity. The COMPARE algorithm 
did not find any match for the observed activity, suggesting either a novel mechanism of action 
or multiple targets. In an effort to explain the selectivity seen in the phenotypic assay, the 
accumulation, retention, and metabolism of 1-1 were determined in renal cancer cells A498, TK-
10, ACHN, and UO-31. Interestingly, lower GI50 concentrations correlated with higher 
accumulation, lower retention, and faster metabolism in the order of A498 > TK-10 >> ACHN ~ 
8 
UO-31. The observation that a faster metabolism correlated with a more potent activity provided 
some early indication that the heterocyclic triad 1-1 may be a prodrug.  
There are dozens of literature reports on potential mechanisms of action of 1-1, but the 
most widely cited study associates 1-1 with binding to the antitumor protein p53, an essential 
defense tool for cells against uncontrolled growth,25 leading to the renaming of the compound to 
RITA (reactivation of p53 and induction of tumor cell apoptosis).26 A common approach for the 
activation of p53 involves targeting the regulatory protein human double minute 2 (HDM2), an 
E3 ligase that binds p53 and then signals it for ubiquitination and subsequent proteasome 
degradation. The discovery and development of the nutlin compounds by Hoffmann-La Roche 
has set the foundation for targeting the p53-HDM2 interaction for antitumor therapeutics.27 
Nultins bind to HDM2 in the same pocket as p53, preventing complex formation and ubiquitin-
mediated degradation of p53.28 Most importantly, they were more selective for cells that 
overexpress HDM2 over healthy cells. Many molecules targeting HDM2 have made it into 
clinical trials for cancer treatment.29  
In contrast to the nutlin series, 1-1 is proposed to bind directly to p53, lending some 
criticism to the proposed activity.26,30 Fluorescence correlation spectroscopy (FCS) showed a 
shift in the diffusion of 1-1 once combined with wild-type p53, indicating an interaction between 
the triad and the protein.26 In contrast, heteronuclear single quantum coherence (HSQC) 
spectroscopy strongly suggested that there is no significant binding between 1-1 and p53 to 
prevent HDM2 binding.30 In addition to targeting wild-type p53, 1-1 showed antitumor activity 
in tumor cells with mutant p53, making it a dual targeting molecule of both wild-type and mutant 
p53.31 This activity was in part rationalized by claiming that mutated p53 undergoes a 
conformational change when 1-1 binds, thus restoring transcriptional activity. CRISPR-Cas9 
9 
based target validation techniques were used to compare the response of lung and colorectal 
cancer to the treatment with either nutlin or 1-1.32 They found that the activity of nutlin was 
strictly dependent on wild-type p53, whereas, 1-1 correlated with induction of DNA-damage and 
cells that were resistant to treatment with 1-1 were also resistant to cisplatin, a DNA crosslinking 
compound.  
In 2011, Spitzer and co-workers looked at 1-1 as a potential DNA minor groove binder.33 
While the compound was a match in the computational model for a minor groove binder, testing 
with Dickerson-Drew dodecamer yielded disappointing results. Nonetheless, 1-1 was shown in 
previous studies to interact covalently with DNA. Studies conducted by the NCI with [14C] 
labeled molecules suggested the formation of DNA-DNA and DNA-protein crosslinks, with the 
latter being more common.15,34 Interestingly, the extent of crosslink formation correlates to the 
cancer cell line response in the NCI-60 assay where the most sensitive cell line A498 formed the 
most crosslinks. The observation that 1-1 does not crosslink purified DNA or proteins provided 
further support that the compound may be a prodrug and the identification of an active 
metabolite may provide important insight into the crosslink formation.34 
Metabolic studies using gas chromatography-mass spectrometry (GC-MS) showed a 14 
amu gain in mass of the bis-TMS protected derivative of 1-1 after incubation in dog liver S9 
fractions.35 Oxidation of one of the terminal alcohols of 1-1 to carboxylic acid 1-6 was suggested 
(Scheme 1). Addition of NADH significantly hindered metabolism, supporting an oxidative 
transformation. Another validation of oxidative transformation of the terminal hydroxymethyl 
groups came in a study by Fraaije and co-workers that showed quadruple oxidation of [5-
(hydroxymethyl)furan-2-yl]methanol (1-7) by FAD-dependent 5-hydroxymethylfurfural oxidase 
to the dicarboxylic acid 1-8 (Scheme 1).36 They also noted that the carbinol group is oxidized 
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significantly faster than the carbaldehyde derivative. They attributed the difference in oxidation 
to the necessity of hydrating aldehydes to diols before oxidation to the carboxylic acid. This 
observation is consistent with the phenotypic screening of related heterocyclic triads that showed 
the aldehyde derivatives of 1-1 to be less active.14 Further studies with cell homogenates 
localized metabolism to cytosolic fractions of the cell and, to a much smaller extent, the nuclear 
and mitochondrial fractions.35 P450 enzymes are not believed to have a significant impact on 1-1 
despite their known metabolic activity on five membered heterocycles.16a While this is 
unexpected, there is precedence in many marketed drugs of mono- and di-substituted five-
membered heterocycles, particularly thiophenes, that are not prone to P450 mediated 
bioactivation.16b  
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Scheme 1. Potential metabolites of 1-1. 
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In addition to oxidation, it was noted that the terminal alcohol groups in 1-1 undergo 
benzylic elimination to produce 1-9 which contains a 2-(exo-methylene) on a terminal thiophene 
ring (Scheme 1).35 The electrophilicity of the exocyclic double bond was demonstrated with the 
nucleophilic attack of methanol and ethanethiol, resulting in methyl ether 1-10 and ethyl 
thioether 1-11, respectively. We believe this elimination may be responsible for the observed 
high-resolution mass spectrometry (HRMS) with the compound mass minus 17 amu, 
corresponding to elimination of a hydroxyl group (see Section 3.2 for specific examples). In a 
biological environment, the exo-methylene moiety may be attacked by a nucleophilic residue 
from DNA or protein resulting in a covalent bond. This is one possibility for the reported 
crosslinking.  
In addition to DNA and p53, other direct or indirect targets have been suggested for 1-1. 
These targets include N-myc,31c Chk2,37 HIF-1,38 JNK/SAPK and p38,39 SULT1A1,40 and 
TrxR1.41 The wide range of targets suggests that 1-1 is likely a non-specific protein binder. The 
broad activity highlights the challenge of preclinical target identification especially when 
measuring downstream phenotypic readouts such as cellular growth inhibition or p53-mediated 
apoptosis.42 
1.1.4 Preclinical Development of NSC 652287  
Even though the biological target of 1-1 is not confirmed, the triad underwent 
considerable development as a preclinical candidate for the treatment RCC.43 The compound was 
highly efficacious in A498 xenograft studies in mice where tumor growth was greatly 
suppressed, as compared to the control group, with an excellent therapeutic index (see Figure 18 
in the Appendix). Some mice were tumor free at the end of the study. Unfortunately, progression 
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of 1-1 into clinical trials was halted due to unacceptable pulmonary toxicity in more advanced 
mammals, dogs and monkeys. The dose-limiting toxicity occurred well below the in vivo 
efficacious dose in mice. Thus, there is an interest in designing analogs of 1-1 that address the 
toxicity concerns, but maintain or increase potency, and allow progression into clinical trials.  
Phenotypic assays can be useful predictors of how a drug’s preclinical evaluation 
translates into clinical performance.44 For example, the NCI-60 panel consists of human-derived 
tumor cells, and designed compounds that have tissue specific activity (i.e. are potent against 
renal cells but inactive against lung cells) may help to overcome the undesired pulmonary 
toxicity of 1-1. Therefore, we hypothesize that improving the cell-selectivity of 1-1 in the 
phenotypic assay by new analog designs may lead to a better therapeutic agent.  
1.1.5 Analog Design and Rationale 
 Since the biological mechanism of action of these compounds is not well understood, 
target-oriented analog designs are not possible. Rather, the design was focused on the chemical 
structure and properties of the heterocyclic triads. Analogs for in vivo testing were prioritized 
based on the information gained from the NCI-60 assay, namely potency and cell-selectivity 
towards A498 cells. 
A survey of compounds previously tested in the NCI-60 provided dozens of hits with 
structures related to 1-1.45 This information provided us with an initial structure-activity 
relationship (SAR) study to assist with the analog design (Figure 4). Our observation for the 
core, highlighted as zone 1, was that triads (3 rings) had better potency and selectivity profiles 
than diads (2 rings) or tetrads (4 rings). Compounds with two or more thiophene or selenophene 
rings showed very high and broad cytotoxicity across the 60 cell lines. While high potency is 
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desirable, the lack of selectivity was a cause for concern. For zone 2, the primary alcohol 
resulted in more desirable activity profiles than amines, carbonyls, carboxylates, and ethers. 
More specifically, two primary alcohols, one on each end of the molecule, outperformed analogs 
with one alcohol moiety. Therefore, from these observations, we decided to leave zone 2 
unchanged, and focus our attention on zone 1.    
1-1
O
SS
OHHO
Zone 1
Zone 2
 
Figure 4. The highlighted zones reflect the focus of the SAR of 1-1 based on compounds 
screened in the NCI-60. 
1.2 RESULTS AND DISCUSSION 
1.2.1 Synthesis of Heterocyclic Triads 
Heterocyclic triads such as 1-1 were previously synthesized by a lengthy stepwise 
approach featuring Suzuki-Miyaura22d or Stille cross-couplings46 of halogenated heterocycles or 
by construction of the central ring via a Paal-Knorr condensation of substituted 1,4-diketones 
(Scheme 2).22c,23,47 The terminal alcohols were, in many cases, accessed by formylation of the 
terminally unsubstituted α-heterocyclic triads.23,47 We envisaged a more direct and efficient 
access to symmetrical triads by palladium catalyzed tandem cross-coupling of readily accessible 
di-halogenated heterocycles, followed by a reduction of the resulting aldehyde or ester to the 
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desired alcohol. This method provided a uniform route for a variety of analogs with high step 
economy from commercially available starting materials.48 
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Scheme 2. Various approaches towards five-membered heterocyclic triads. 
The Suzuki-Miyaura cross-coupling was utilized to form triads of five-membered 
heterocycles containing one heteroatom (Schemes 3 – 5).48 Several Pd(0)/ligand combinations 
were screened and the combination Pd2(dba)3 and tri-tert-butylphosphine provided the best 
cross-coupling yield under microwave irradiation.49 Other ligands such as JohnPhos,50 
triisopropyl phosphine, and tricyclohexylphosphine gave yields below 25% of 1-14a. Mono-
coupling was attempted by using an excess of halide 1-12a with the ligand XPhos;51 however, 
bis-coupled 1-14a was the major product. In comparison, Pd(PPh3)4 with tetra-N-
butylammonium bromide as an additive gave a mixture of mono-coupled (major) and bis-
coupled (minor) products.52  
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Scheme 3. Tandem Suzuki-Miyaura cross-coupling of 2,5-dibrominated furan, thiophene, and 
selenophene followed by reduction to diols.48  
Commercially available boronic acid 1-13a was coupled with readily accessible 
dibrominated heterocycles 1-12a–f (Schemes 3 and 4).48 Bis-coupling at the 2,5-positions of 
dibrominated furan 1-12a, thiophene 1-12b, and selenophene 1-12c was achieved in good to 
excellent yields (Scheme 3). Interestingly, coupling products 1-14b and 1-14c were observed as 
yellow precipitates in the reaction mixture at room temperature immediately after addition of all 
reaction components, and when left stirring overnight at room temperature, aldehyde 1-14b was 
obtained in >70% yield. While the reaction proceeds at room temperature, microwave conditions 
greatly expedited reaction completion without signs of decomposition. Finally, reduction of the 
aldehydes 1-14a–c with NaBH4 furnished the alcohols 1-15a–c in excellent yields. These 
reactions were successfully scaled-up to multi-gram scale for producing quantities sufficient for 
in vivo studies (Section 1.2.5).  
Similarly, regioisomeric analogs with 3,4- and 2,4-substitutions on the central heterocycle 
were obtained by bis-coupling of 1-13a to 3,4-dibromothiophene (1-14d), 2,5-dimethyl-3,4-
dibromothiophene (1-14e), and 2,4-dibromothiophene (1-14f) (Scheme 4).48 Due to the lower 
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reactivity at C(3) of thiophene,53 we increased the catalyst loadings and equivalents of boronic 
acid 1-13a to facilitate conversion of 1-12d–f to the bis-coupled products 1-14d–f in moderate to 
excellent yields. Subsequent NaBH4 reduction furnished the diols 1-15d–f in excellent yields. 
Proton nuclear magnetic resonance (NMR) analysis of analog 1-15d revealed decomposition in 
the form of additional aromatic and nonaromatic peaks upon mild heating to ca. 50 °C, 
presumably due to the high reactivity of the unsubstituted C(2) and C(5) on the central electron-
rich thiophene ring. This observation signals a potential instability of the 3,4-substituted analogs. 
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Scheme 4. Tandem Suzuki-Miyaura cross-coupling of 3,4- and 2,4-dibrominated thiophene 
followed by reduction to diols.48 
The symmetrical analogs were rapidly constructed by bis cross-coupling of dihalogenated 
heterocycles. Even though selective mono-coupling of the 5-position of 2,3,5-tribromothiophene 
has been previously demonstrated,54 it was difficult to prevent bis-coupling on the 2,5-
dibromothiophene and a mixture of products was obtained. Therefore, desymmetrized analog 1-
15g was constructed in a complementary stepwise approach, using the optimized Suzuki-
Miyaura conditions (Scheme 5).48 Commercially available halide 1-12g and boronic acid 1-13b 
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were coupled, and the resulting product was subsequently brominated with N-bromosuccinimide 
and benzoyl peroxide55 to yield 1-16 in 61% over the two steps. Aryl bromide 1-16 and boronic 
acid 1-13a were coupled to yield 1-14g in 78% yield, and reduction of the aldehyde functional 
groups with NaBH4 provided diol 1-15g in 90% yield.  
S BrOHC O B(OH)2
O
SOHC
rt, 2 h; 90%
+
1-14g 1-15g
1-161-13b1-12g
1,4-dioxane/H2O
µW 70 °C, 30 min; 78%
NaBH4
THF/MeOH
1. Pd2(dba)3 (1 mol%)     
t-Bu3P (6 mol%), Na2CO3   
1,4-dioxane/H2O,
 
µW 70°C, 30 min
1-13a, Pd2(dba)3 (1 mol%) 
t-Bu3P (6 mol%)
Na2CO3
2. NBS, (BzO)2, toluene    
-15 °C, 6 h; 61%
CHOOHC OS
O
OHHO
OS
O
Br
 
Scheme 5. Sequential Suzuki-Miyaura cross-couplings for the synthesis of desymmetrized 
analog 1-15g.48 
Since bromo-furans are highly unstable upon storage, we opted for the lengthier stepwise 
approach to synthesize 1-1 (Scheme 6). The synthesis of a tetrad analog was also attempted, 
using a similar route, featuring four thiophene rings all substituted in the 2,5-postions, but the 
solubility of this analog in organic and aqueous solvents was highly limited. It is therefore highly 
unlikely that this compound would perform well in bioassays.   
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Scheme 6. Synthesis of NSC 652287 (1-1). 
With diols 1-15a–g in hand, we sought to diversify the analog library by incorporating an 
oxazole into the scaffold, ideally through a similar bis cross-coupling method (Scheme 7).48 
Ethyl 2-iodo-4-oxazole carboxylate (1-17) and the organozinc iodide 1-18 were prepared in order 
to attempt Suzuki and Negishi cross-couplings, respectively. These methods yielded only trace 
amounts of the desired bis coupled product 1-19a. 
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Scheme 7. Attempted cross-couplings on functionalized oxazoles. 
The challenge of functionalizing and coupling oxazoles56 was circumvented by 
expanding on a direct regioselective arylation strategy via C-H activation of commercially 
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available oxazole ester 1-20. The Hoarau group reported the selective arylation of either the C(2) 
and C(5) positions of 1-20 using palladium catalysis.57 The electron-withdrawing nature of the 
ester was reported to be important for the reactivity of the oxazole, particularly for the activation 
and deprotonation of C(2)-H.58 Our attempts to couple the carbinol and aldehyde derivatives of 
1-20 under the same conditions were unsuccessful. However, 1-20 underwent a C(2) selective 
dual C-H activation/cross-coupling with 1-12b–c using Hoarau’s conditions to furnish esters 1-
19a–b in good yields (Scheme 8).48 Additionally, the position of the ester on the oxazole ring 
influences reactivity. When we attempted the coupling with ethyl-5-oxazole carboxylate under 
identical conditions, only 5% of the bis coupled product was isolated, reinforcing the need for 
electron withdrawing group at C(4). With 1-19a–b, we extended the Hoarau methodology by 
applying a dihalogenated coupling partner and performing a tandem cross-coupling. Finally, 
LiAlH4 reduction of the ester functionality provided access to the desired alcohols 1-21a–b in 
good yields.  
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Scheme 8. Sequential Pd-catalyzed C-H bond activation/cross coupling of oxazoles with 
dibromothiophene and dibromoselenophene followed by reduction to diol.48  
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The central ring was further diversified by the incorporation of a triazole (Scheme 9). The 
reaction sequence began with the Fischer esterification of brominated furoic acid 1-22 with 
concentrated sulfuric acid in ethanol to yield ester 1-23 in 93%. Sonogashira coupling and 
subsequent TMS deprotection yielded alkyne 1-24 in 65% yield over two steps.59 In situ 
formation of aryl azide on 1-23 followed by copper(I)-catalyzed azide/alkyne cycloaddition 
(CuAAC) with 1-24 gave 1,4-substituted 1,2,3-triazole 1-25 in 62% yield.60 LiAlH4 reduction 
gave access to diol 1-26 in 83%. 
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Scheme 9. Synthesis of 1,4-substituted 1,2,3-triazole by Cu-catalyzed azide-alkyne 
cycloaddition followed by reduction of ester groups to alcohols. 
1.2.2 NCI-60 Cell Assay 
Diols 1-15a–g, 1-21a–b, 1-26 and aldehyde 1-14c were evaluated in the NCI-60 cell 
panel for anticancer activity. With the exception of triazole-containing analog 1-26 and oxazole-
containing analogs 1-21a–b, which provided no significant cell growth inhibition at 10 µM 
concentration, the heterocyclic triads were active and, in general, more selective towards the 
renal cell line A498 over other cell lines (Table 1). 
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NSC 652287 (1-1) showed a GI50 of about 15 nM with a hyperactive profile (Table 1, see 
the Appendix for the complete cell panel profiles of 1-1, 1-15b, 1-15c, and 1-15f). Replacing the 
terminal thiophenes in 1-1 with terminal furans in analogs 1-15a–c resulted in a ten-fold 
reduction in potency but higher cell-selectivity. Aldehyde 1-14c was nearly a hundred-fold less 
active than 1-1 and ten-fold less active than the reduced selenophene analog 1-15c. Interestingly, 
analog 1-15g, the sequence isomer of 1-15b, placed a thiophene ring on one terminal end with a 
furan as the central ring and resulted in the same potency as 1-1, also with low selectivity. 
Changing the triad geometry by altering the substitution positions on the central ring in 1-15d–e 
retained the same potency and low selectivity as 1-1 and 1-15g despite having terminal furans. 
However, the 2,4-substituted analog 1-15f was equipotent to 1-1 but with the highest cell-
selectivity of all analogs.  
Table 1. Growth inhibition in renal (A498), lung (NCI-H226), kidney (CAKI-1), and breast 
(MDA-MB-468, MCF7) cancer cell lines in the NCI-60 cell assay. 
entry compd/NSC no. GI50a (µM) GI50b (µM) Selectivity towards A498c 
1 1-1, 652287 0.012 (CAKI-1) 0.015 (A498) Low 
2 1-15a, 672348 0.18 (A498) 0.58 (NCI-H226) High 
3 1-15b, 773097 0.13 (A498) 0.17 (MDA-MB-468) High 
4 1-14c, 773393 0.30 ± 6.1 (A498) 6.3 (MCF7) High 
5 1-15c, 773392 0.17 (A498) 0.22 (MDA-MB-468) High 
6 1-15d, 777422 0.015 (A498) 0.074 (MDA-MB-468) Low 
7 1-15e, 778301 0.016 (MDA-MB-468) 0.018 (A498) Low 
8 1-15f, 782846  0.020 (A498) 0.11 (MDA-MB-468) High 
9 1-15g, 777196 0.016 (A498) 0.018 (MDA-MB-468) Low 
aMost sensitive cell line; bSecond most sensitive cell line; cHigh selectivity indicates that the GI50 
values of ≤6 cell lines (≤10% of NCI-60 panel) were within 50x of the A498 GI50 value and low 
selectivity indicates that the GI50 values of >6 cell lines (>10% of NCI-60 panel) were within 
50x of the A498 GI50 value. 
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The oxazole and triazole containing analogs were inactive, presumably due to the 
instability of the polyheteroatom-containing rings. The oxazole analog 1-21b showed signs of 
decomposition by 1H NMR when left overnight in a solution of deuterated dimethyl sulfoxide 
(DMSO). The aromatic peaks became complex and new nonaromatic peaks appeared, 
presumably from oxazole ring opening. Since the biological assay is conducted with the 
compounds dissolved in DMSO, it is likely that the analogs decomposed before testing. The 
triazole analog 1-26 formed reversible adducts with solvents, particularly methanol, as detected 
by 1H NMR. We hypothesized the formation of the diazo/imine tautomer,61 but no conclusive 
evidence of ring opening by infrared (IR) or ultraviolet (UV) spectroscopy was found. 
1.2.3 Chemical and Metabolic Stability of Heterocyclic Triads 
The SAR of 1-1 revealed that small changes in the triad structure can have significant 
impact on the potency and cell-selectivity in the NCI-60 assay. For example, analogs 1-15b and 
1-15g only differ in the sequence of the heterocycles; 1-15b has a central thiophene and 1-15g 
has a terminal thiophene. Interestingly, the high potency but poor selectivity of 1-15g resembles 
the profile of 1-1 whereas 1-15b is less potent but more selective. This observation suggests that 
the sulfur atom in the terminal rings may play a role in the observed bioactivity. However, 
analog 1-15f was equipotent to 1-1 and does not feature a terminal thiophene. Instead, 1-15f 
differs from the less potent 1-15b by the geometry of the substitution on the central ring. To gain 
a greater insight into the causes for the influence of the 2,4-geometry of 1-15f and the 2,5-
geometry of 1-1 and 1-15b on activity, we studied the chemical stability of these triads. 
 We noticed considerable differences in the color of the three triads when dissolved in 
DMSO. Triad 1-1 formed a very bright yellow-green and slightly fluorescent solution. The 
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solution of analog 1-15b in DMSO was also bright yellow, but 1-15f was only pale yellow and 
formed a clear solution. These observations were supported by UV-Vis spectroscopy, since 1-1 
and 1-15b absorbed at higher wavelengths than 1-15f (Table 2). The dialdehyde derivatives of 
the triads, 1-14f and 1-14h had an even higher absorption wavelength as would be expected with 
the added conjugation of the carbonyl groups. Triads 1-1 and 1-15b are fully conjugated across 
the three rings, whereas 1-15f has a cross-conjugation that prevents direct electron flow across 
all three rings (Figure 5). HOMO-LUMO gaps were calculated and showed that the gap in 1-15f 
is ca. 10 kcal/mol greater than the gaps in the 2-5-substituted triads. 
Table 2. Ultra-violet/visible light spectroscopy of heterocyclic triads in MeOH. 
entry Compound λmax (nm) 
1 1-1 358.5, 264.5 
2 1-14h 409.0, 291.0 
3 1-15b 357.0, 245.0 
4 1-15f 281.5 
5 1-14f 330.5, 217.0 
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Figure 5. The 2,5-substituted triads 1-1 and 1-15b are fully conjugated across the three rings, 
whereas the 2,4-substituted triad 1-15f has a cross-conjugation that prevents direct electron flow 
across all three rings. HOMO-LUMO gaps were computed from optimized structures at the DFT 
level of approximation using BIOVIA Materials DMol3 (2016, v.16.1.0.21) using the PW91 
functional.62 
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Given the known electron and optical properties of oligo-heterocycles24,63 and the 
observed physical properties of the triads, we postulated that the triads may be prone to light 
mediated degradation. Solutions of 1-1 and 1-15f in methanol were stirred at room temperature 
next to a 23 W compact fluorescent lamp (CFL) for 18 h. Analysis of the reaction mixtures 
revealed that 1-1 readily decomposed (<30% remaining) to form new oxidation products, 
whereas 1-15f was significantly unchanged (>85% remaining) by 1H NMR analysis.  
For further studies, the solution stability of triads 1-1, 1-15b, and 1-15f in DMSO-d6/D2O 
at 1 mg/mL at room temperature under ambient light was monitored by 1H NMR. Within one 
week, significant decomposition (>30%) of 1-1 and 1-15b was observed. The degradation studies 
were scaled-up to 15 mg in 2 mL of DMSO-d6. Based on 1D and 2D NMR monitoring along 
with high resolution LC-MS, we assigned tentative structures for the main decomposition 
products of 1-1 (Figure 6). Both products arise from the oxidative ring opening of the central 
furan ring. Due to the symmetry of 1-27, it was unclear whether the double bond was the E- or Z- 
isomer. The decomposition products of 1-15b were not well defined, instead the NMR was very 
messy. In contrast, after two weeks in solution, 1-15f remained >95% unchanged. To better 
understand the properties of these compounds in the biological assays, a mouse plasma stability 
assay was conducted (Table 3). Triads 1-1, 1-15b, and 1-15f were mostly stable in plasma after 
incubation for 3 hours at 37 °C. A mouse liver microsome assay is planned for these compounds. 
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Figure 6. Tentative assignment of the major degradation products of 1-1. 
Table 3. Plasma stability assay with triads 1-1, 1-15b, and 1-15f. 
  amount remaining after specified incubation time with plasmaa 
entry compound no incubationb 1.5 h 3 h 
1 procaine  (positive control) 100% ~ 5% <5% 
2 procainamide  (negative control) 100% >99% >99% 
3 1-1 100% >90% ~90% 
4 1-15b 100% >99% >95% 
5 1-15f 100% >99% >99% 
aCompounds were tested at 10 µM by incubating in a mixture of mouse plasma and PBS pH 7.4 
(1:1) at 37 °C. The amount remaining was quantified using high-resolution LC/MS with an 
internal standard (caffeine); n = 3. bSamples were quenched immediately after addition of 
plasma.  
The degradation products of 1-1 from our studies differ from the metabolites suggested in 
previous reports (Section 1.1.3, Scheme 1), and these compounds can potentially act as 
electrophilic Michael acceptors in a biological system. These observations highlight the 
complexity of studying the mechanism of action of this compound and may contribute to the fact 
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that a wide variety of biological targets have been postulated. Furthermore, it is remarkable that 
analog 1-15f is equipotent to 1-1 without exhibiting similar degradation kinetics. 
1.2.4 Thermal Shift Assay and Mass Spectrometry for Target Identification 
Over the past three decades, a target-oriented approach to developing new anticancer 
therapeutic agents has emerged and resulted in many approved drugs.64 When the biological 
target is known, the exact nature of the interaction between the target and the drug molecule can 
be studied in great detail with various analytical methods, such as NMR, X-ray crystallography, 
and cryo-electron microscopy.65 In contrast, lead molecules identified via a phenotypic screen, 
such as the NCI-60 cell assay, are chosen without prior knowledge of the biological targets. 
Consequently, it is possible that each triad acts differently once it enters the cell. Based on the 
previous studies on 1-1 discussed in Section 1.1.3, we hypothesized that cell-active triads indeed 
bind to multiple biological targets. 
Unknown drug interactions with biological targets can be identified by a variety of 
techniques such isotopic labeling, fluorescence imaging, affinity binding, and protein pull-down 
studies.66 However, techniques that can avoid any cumbersome chemical modifications to the 
small molecules are more desirable since these modifications may impact the biological and 
physical properties of the test compounds. In recent years, the thermal shift assay has been 
developed where protein-ligand interactions can be surveyed in cell lysates and whole cells 
without the need of any chemical modification of the drug compounds.67 
The non-covalent interaction of a ligand molecule with a protein is thermodynamically 
driven. In order for the interaction to be favorable in the cellular environment, the binding of the 
small molecule to a protein should alter its conformation into a more stable structure. The 
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thermal shift assay is predicated on the concept that applying heat to a pool of proteins will cause 
them to denature and precipitate out of solution (Figure 7). If a ligand molecule is bound to the 
protein, the extra stabilization gained from the binding will protect the protein from thermal 
denaturation and the protein will remain in solution at higher temperature. This increased 
stability can then be measured as an indication that the protein is a potential target for the small 
molecule. 
Current methods use post-thermal assay labeling with tandem mass tags of analytes 
subjected to different temperatures followed by protein identification and quantification by LC-
MS/MS67b or Western blots to compare the relative band intensity of drug-treated samples and 
the control.67a  The Yates group at the University of Pittsburgh is developing a new approach that 
uses differential mass spectrometry to quantify the protein readouts following the thermal shift 
assay (Figure 7).68 This approach is tag-free and does not require post-assay modification of the 
analyte mixtures. Proteins are separated by liquid chromatography and their identity determined 
by MS/MS techniques. The protein concentrations of the drug-treated group are compared to 
vehicle controls, under otherwise identical experimental conditions. Any proteins that undergo a 
statistically significant positive fold change in the treated samples (vs. control) are deemed of 
interest.  
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Figure 7. Overview of the thermal shift assay coupled with differential mass spectrometry. 
The effects of compounds 1-1, 1-15b, and 1-15f on the proteome were tested in the 
thermal shift assay on cell lysates derived from cultures of the renal cell carcinoma A498 
(Figures 8-10).68 After treatment with either a vehicle (DMSO) or test compound, the lysates 
were heated to 56 °C to induce thermal degradation of the proteins. The remaining soluble 
proteins in the supernatant were collected, purified, lysed with trypsin, and then measured by 
nanoLC-MS/MS. The analyte was identified by a computer platform (i.e. MaxQuant),69 
quantified, and subjected to rigorous statistical analysis to measure for significant positive fold 
change in protein amounts between the drug treated group and vehicle control (Figures 8-10). In 
Table 4, the top five protein hits are summarized for triads 1-1, 1-15b, and 1-15f resulting from 
the thermal shift assay using the lysates from A498 cells. This preliminary data represents the 
potential that these compounds have many different targets. Most of these protein hits are 
typically located in the cytoplasm of cells. However, since this assay was conducted on cell 
lysates, the significance of the subcellular localization of the targeted proteins can’t be 
determined. Currently, we are conducting the assay in whole cells to evaluate the localization of 
protein hits and to address the possibility of the triads being prodrugs. Furthermore, the thermal 
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assay is not conclusive on its own of the drug interaction with proteins. We will validate the 
protein hits with separate in vitro assays. 
 
Figure 8. Comparison of the proteins remaining in solution between the vehicle control (DMSO) 
and 1-1 treated A498 cell lysate after the thermal shift assay at 56 °C. 
 
Figure 9. Comparison of the proteins remaining in solution between the vehicle control (DMSO) 
and 1-15b treated A498 cell lysate after the thermal shift assay at 56 °C. 
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Figure 10. Comparison of the proteins remaining in solution between the vehicle control 
(DMSO) and 1-15f treated A498 cell lysate after the thermal shift assay at 56 °C. 
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Table 4. Top five protein hits for compounds 1-1, 1-15b, and 1-15f in the thermal shift assay 
using lysates derived from A498 cells. 
protein rank test compound: 1-1  references 
1a Glycosyl-phosphatidylinositol-anchored molecule-like protein (GML)  70 
1b Thioredoxin reductase 1 (TXNRD1)a 41, 71 
2 Glutathione S-transferase Mu 1 (GSTM1) 72 
3 5-Aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) 73 
4 Aldo-keto reductase 1C3 (AKR1C3) 74 
5 G-protein subunit alpha i2 (GNAI2) 75 
protein rank test compound: 1-15b references 
1 Sulfotransferase 1A1 and 1A2 (SULT1A1; SULT1A2)a 40,76 
2 Carbonyl reductase 1 (CBR1) 77 
3 Heterogeneous nuclear ribonucleoprotein U (hnRNP U) 78 
4 Biliverdin reductase B (BLVRB) 79 
5 Actinin Alpha 4 (ACTN4) 80 
protein rank test compound: 1-15f references 
1 AKR1C3 74 
2 Fatty acid synthase (FASN) 81 
3 Annexin A1 (ANXA1) 82 
4 ATPase Na+/K+ transporting subunit alpha 1 (ATP1A1) 83 
5 Annexin A2 (ANXA2) 82 
aPreviously linked to 1-1.  
1.2.5 A498 Xenograft Studies in Mice with 1-15b and 1-15c 
The heterocyclic scaffold proved to be quite versatile in that changes to the identity and 
the geometry of the tricyclic core yielded significantly different activity and cell-selectivity in 
the NCI-60 assay. We saw different combinations of potency and degree of cell-selectivity, 
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however, the renal cell line A498 was a constant target for all active analogs (1.2.2).  We are 
interested in determining whether increased cell-selectivity translates to a better therapeutic 
index in in vivo studies and a predictor of toxicity. All biological studies were conducted by the 
NCI Developmental Therapeutics Program.45 
NSC 652287 (1-1) has been previously tested in A498 cell line xenograft models where it 
showed significant inhibition of tumor growth as compared to a DMSO-treated control group 
with treatment doses ranging from 27 mg/kg/dose to 90 mg/kg/dose (see Appendix; Figure 18). 
Two lead compounds 1-15b and 1-15c were selected as representatives of cell-selective activity 
profiles for testing in a A498 cell line mouse xenograft models to enable comparison with the 
broadly cytotoxic 1-1. The complete NCI-60 cell panel for 1-1, 1-15b, and 1-15c are shown in 
Appendix A (Figures 20 – 23). At the time, we were unaware of the NCI-60 activity of 1-15f, 
therefore the compound was not selected for testing in animal models (although these tests are 
planned).  
Triads 1-15b and 1-15c were tested in A498 xenograft studies in mice under identical 
experimental conditions (Figure 11 and Figure 12). The activity was compared to a control group 
consisting of 16 mice treated with only DMSO. There were 8 mice in each compound-treated 
group and the compounds were delivered by intraperitoneal injections (IP). Due to the lower 
potency seen in the cell assay, the treatment dose was set at 200 mg/kg/dose. Tumor size was 
monitored during treatment (days 17-21 post-implant) and for ca. 60 days after treatment 
delivery was completed.  
Treatment with compound 1-15b showed impressive inhibition of tumor growth that 
persisted for ca. 45 days post-treatment (Figure 11). The net mouse body weight showed a slight 
average decrease in weight, ca. 2-3 g, when the treatment was administered; however, the net 
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mouse body weight quickly recovered once the treatment was completed (Figure 12). Notably, 
there were no drug-related deaths and one mouse was found to be tumor free at the end of the 
study.  
Results for the selenophene analog 1-15c were nearly identical to the related thiophene 
analogue 1-15b during treatment (Figure 11). Likewise, there were no drug-related deaths and 
significant tumor growth suppression was observed while treatment was administered. However, 
significant tumor growth resumed after ca. 20 days after treatment was completed, compared to 
ca. 45 days with compounds 1-1 and 1-15b. Overall, while tumor growth was suppressed, near 
the end of the study it appeared that the positive effects of the treatment were diminishing and 
tumor growth was returning, highlighting the difficulty of treating RCC as discussed earlier 
(Section 1.1.1). 
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Figure 11. A498 cell line xenograft study with NSC 773097 (1-15b) and 773392 (1-15c). Mice 
were treated by intraperitoneal injections on days 17-21 post implant. Bars reflect ± scaled 
median absolute deviation.45 
 
Figure 12. Mean mouse weight response to 1-15b and 1-15c in A498 xenograft study.45 
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A selective activity profile is often desired in therapeutic agents to minimize off-target 
effects and toxicity. The in vivo tumor suppression profiles for 1-15b and 1-1 are nearly 
identical. The main difference is that the tested dose for 1-15b is 2-7 times greater than for 1-1. 
Since the efficacious dose is the main variable in determining the therapeutic index, more 
extensive toxicology studies are necessary in order to better judge the connection of the NCI-60 
assay cell-selectivity and the therapeutic index. 
1.3 CONCLUSION 
 Five-membered heterocycles offer a privileged scaffold in medicinal chemistry where 
wide variations in electron density, structural geometry, and physical properties are accessible. 
The broadly cytotoxic triad 1-1, consisting of three linked five-membered heterocycles, showed 
significant tumor inhibition without any drug related deaths in A498 xenograft studies in mice 
over the course of 75 days. However, studies with 1-1 were halted after discovery of severe 
toxicity in larger mammals. The tunability of heterocycles enabled the design and synthesis of 
novel analogs of 1-1 with improved cell-selectivity in the NCI-60 assay. 
Our studies have shown that the activity and potency of 1-1 can be altered by replacing 
the terminal thiophenes with furans and changing the substitution pattern on the central ring, thus 
limiting the accessibility of the sulfur atoms to oxidative pathways. Interestingly, changing the 
triad geometry from 2,5-substitution pattern on the central thiophene of 1-15b to the 2,4-
substitution in 1-15f improved both the potency and cell-selectivity towards A498 in the NCI-60 
assay. Moreover, chemical stability studies showed that the 2,4-substitution in 1-15f made the 
compound more stable than the 2,5-substituted 1-15b and 1-1. Preliminary results from the 
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thermal shift assay for target identification revealed that the triads likely bind many biological 
targets.  Xenograft studies with 1-15b showed that a tumor growth suppression comparable to 1-
1 can be achieved by using a higher drug dose. Xenograft studies with 1-15f are planned for the 
near future. The initial assessment of these compounds shows promise for their use for the 
treatment of renal cell carcinoma. However, additional studies are needed to determine if high 
cell-selectivity in the NCI-60 assay translate to an improved therapeutic index.  
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2.0 SMALL MOLECULE MODULATORS OF PROTEIN TYROSINE 
PHOSPHATASE 4A3 ACTIVITY 
2.1 INTRODUCTION 
2.1.1 Protein Tyrosine Phosphatase 4A3 as a Therapeutic Target  
 The reversible phosphorylation of the hydroxylated moieties of serine, threonine, and 
tyrosine residues is a key mechanism for eukaryotic cells to regulate enzymatic activity, respond 
to extracellular signals, and manage various pathways.84 This reversibility is managed by kinases 
and phosphatases, which create an essential balance of activating and deactivating substrates. 
The human genome encodes for >500 protein kinases and >125 protein phosphatases.84b,85 
Historically, targeted drug discovery efforts have been biased towards kinase inhibition resulting 
in >35 FDA-approved drugs.86 Meanwhile, targeting phosphatases in drug discovery remains 
largely underdeveloped with no approved drugs. Recent studies have revealed that protein 
tyrosine phosphatases are highly regulated by protein oligomerization, redox control, and 
allosteric modulation allowing for specific control of cellular signaling pathways.87 When these 
pathways are associated with human diseases, targeting phosphates provides an opportunity for 
novel discoveries of selective inhibitors and expansion of current therapeutic options.86a,88 
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Protein tyrosine phosphatases 4A (PTP4A), formerly known as phosphatases of 
regenerating liver (PRL), have garnered interest in recent years as anticancer targets. There are a 
number of comprehensive reviews detailing the validation of PTP4A as biomarkers and 
therapeutic targets in cancer.89 Three proteins in this family have been identified: PTP4A1, 
PTP4A2, and PTP4A3. From this family of phosphatases, PTP4A3 is of particular interest as it 
has a higher rate of overexpression in cancer cells than other phosphatases, including PTP4A1 
and PTP4A2. Comparison of gene expression profiles in colon cancers which metastasized to the 
liver showed that, among 144 upregulated genes, only PTP4A3 was overexpressed in all the 
colon cancer metastases studied.90 Additionally, PTP4A3 is also overexpressed in breast, lung, 
cervical, ovarian, and gastric cancers.89c PTP4A3 was validated as anticancer target in vivo 
where PTP4A3-deficient mice showed decreased clonogenicity and tumor-initiation ability 
without gross histological abnormalities in normal tissues.91 Furthermore, there was decreased 
tumor driven angiogenesis, VEGF-dependent endothelial cell motility, and vascular 
permeability. Overall, PTP4A3 seems to play a larger role in tumor cells than in normal cells. 
Consequently, targeting PTP4A3 in cancer therapy may have limited untoward effects. Even 
though no endogenous substrates of PTP4A3 have been confirmed, several downstream 
signaling pathways that may have serious implications in cancer have been linked to PTP4A3 
including PI3K/AKT,92 Rho GTPases,93 ERK1/2,94 and Src.95 Therefore, the discovery of small 
molecule modulators of PTP4A3 will enable the detailed exploration of these pathways and 
elucidation of its biological role in cancer tumorigenesis and metastasis.96 
39 
2.1.2 Structural Features of the Protein Tyrosine Phosphatase 4A Family 
There is considerable conservation of sequence identity between the PTP4A proteins 
(Figure 13). PTP4A1 shares 86% identity with PTP4A2 and 78% with PTP4A3.89a Notably, 
there is a conserved C49 residue (C46 in PTP4A2), WPD loop, and a C(X)5R active site 
phosphatase domain.  
 
Figure 13. Aligned sequences of the PTP4A family showing sequence similarities including 
identical WDP loop and C(X)5R active site domain.89 
Even though there is no X-ray crystal structure for these proteins with a native or drug 
substrate in the active site, the crystal structure of PTP4A1 and the NMR solution structure of 
PTP4A3 provide meaningful insights into the role of the conserved residues in the activity of the 
PTP4A family (Figure 14).89a,89c,97 The C49 (C46 in PTP4A2) residue plays a key role in 
regulating the activity of PTP4A by forming a disulfide bond with C104 (C101 in PTP4A2) of 
the C(X)5R domain. Redox driven dissociation and formation of the disulfide bond can regulate 
the activity of the proteins by, respectively, opening and closing the active site pocket. The 
proline residue in the WPD loop can provide the shape and size flexibility needed to form the 
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other end of the active site. One proposed difference in the structures of PTP4A1 and PTP4A3 is 
the orientation of the C104 and R110 side chains. In PTP4A3, these chains seem to point away 
from the active site.89a Since the two structures do not have any substrates in the active site, any 
structural observation is somewhat uncertain. 
The proposed mechanism of dephosphorylation involves the C(X)5R and WPD domains 
(Figure 14).89c R110 (R107 in PTP4A2) in the C(X)5R domain plays a role in stabilizing the 
incoming negative charge(s) on the substrate, positioning the substrate in the pocket, and 
increasing the electrophilicity of the phosphorous atom in the phosphate group. Then, C104 can 
act as a nucleophile and attack the phosphorous resulting in the release of a phenoxide anion that 
is quickly protonated by D72 of the WPD loop. The resulting thiophosphate group can then be 
hydrolyzed to regenerate the cysteine residue and a phosphate group. 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Active site of PTP4A family based on the crystal structure of PTP4A1 (top left, pdb 
code 1X24), NMR solution structure of PTP4A3 (top right, pdb code 2MBC), and proposed 
mechanism of dephosphorylating a tyrosine containing substrate (bottom). 
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 The phenotypic importance of PTP4A3 is well known, but the exact details of its activity 
is not well understood. There are many known inhibitors of PTP4A that were highlighted in a 
recent review by Sharlow et al. (Figure 15).89c Even though some of these inhibitors are sub-
micromolar active, they contain many undesired structural features such as quinones, phenols, 
and Michael acceptors. These structural liabilities may contribute to alkylative binding, which 
presents possible selectivity, irreversible inhibition, and toxicity issues in vivo. Ideally, a novel 
inhibitor should improve on the potency and selectivity of known inhibitors while eliminating 
the potential for nonspecific covalent interactions. 
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Figure 15. A selection of known PTP4A inhibitors with in vitro IC50 (µM). 
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Pentamidine is a pan inhibitor of PTP4A at submicromolar concentrations.98 However, it, 
as well as structurally similar amidines, lacks specificity due to binding to DNA and RNA 
polynucleotides, likely through hydrogen bonding between the protonated terminal amidine 
functionalities and nucleotides in the minor groove.99 Two naturally occurring bioflavonoids, 
ginkgetin and sciadopitysin, have double digit micromolar activity against PTP4A3.100 The large 
molecular weight, multiple phenolic hydroxyl groups,101 and Michael acceptors102 cause concern 
for further development due to potential toxicity and irreversible binding. Emodin, likewise, 
suffers from quinone and polyphenolic features.103 CHM-1-P-Na shows an interesting selectivity 
with 10-fold higher potency towards PTP4A1 and PTP4A2 over PTP4A3.104 While this 
compound may be further optimized, PTP4A3 is a more attractive therapeutic target, as noted in 
section 2.1.1, therefore this selectivity is undesired. For CG-707 and BR-1 (2-1), there is an 
ongoing debate about the usefulness of rhodanines in medicinal chemistry.105 Rhodanines are 
known to participate in an alkylation mechanism of action and aggregate in cells leading to 
disruption of cellular processes. Furthermore, CG-707 and 2-1 contain a potential Michael 
acceptor with an exo-methylene group. Nonetheless, these rhodanine-containing compounds 
provide attractive potency and a promising starting point for designing a new scaffold. Finally, 
thienopyridone 2-2 showed the best reported potency to date against PTP4A3. One drawback of 
this compound is the potential for hydroquinone/quinone type redox activity.  
2.1.3 Analog design based on BR-1 and Thienopyridone 
 Small molecule modulators of protein activity can be highly useful tools in elucidating 
signaling pathways, protein substrates, and cellular responses.88e,106 The modulator must be 
potent but also selective for the target protein. For the molecule design, we considered building 
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on the existing scaffolds of 2-1 and 2-2. From a synthetic point of view, 2-1 was chosen over 
CG-707 because of simpler structural features. The orientation and extension of the aromatic 
rings that is provided by the additional alkene in CG-707 does not seem to contribute to activity.  
 High throughput screening of the Korean Chemical Bank identified the rhodanine 
scaffolds as potential inhibitors of PTP4A3.107 After SAR studies, 2-1 was identified as a lead 
inhibitor.107-108 PTP4A3 was confirmed as target of 2-1 by the recovery of phosphorylated ezrin 
and cytokeratin 8, putative substrates of PTP4A3.108 Selectivity toward PTP4A3 was 
demonstrated against 10 other phosphatases. Additional studies showed the inhibition of 
migration and invasion activity of PTP4A3 overexpressing colon cancer cells (DLD-1 (PRL-3)) 
without exhibiting cytotoxicity or inhibiting proliferation.108  
 A hypothesis was offered for the mode by which 2-1 binds to the active site of 
PTP4A3.107 It was suggested that the nitrogen in the rhodanine ring is deprotonated and the 
resulting negative charge is stabilized by the positive charge of the Arg residue in the active site. 
This observation was further supported when the N-methylated derivative of 2-1 showed no 
activity. However, this hypothesis does not consider the possibility of alkylative binding. It is 
possible that deprotonated 2-1 acts as a nucleophile and forms an irreversible covalent bond with 
an electrophile. The alkylative mechanism is equally supported by the observation of no activity 
with the N-methylated 2-1. It is also possible that the true mechanism of action may involve 
some balance of alkylative and non-alkylative activity. Further, SAR studies on 2-1 revealed that 
the thione in the rhodanine ring is essential for activity.108 When the sulfur atom was replaced 
with an oxygen atom, the activity significantly decreased. 
Thienopyridone 2-2 was the most potent known inhibitor at the time (IC50 PTP4A3 = 
0.13 µM).109 It was shown to be selective for the PTP4A family over 11 other phosphatases. 
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Significant inhibition of tumor cell anchorage-independent growth, induction of p130Cas 
cleavage, and apoptosis that is not related to increased levels of p53 were observed. The main 
concern with this compound is the potential for hydroquinone/quinone type redox activity 
resulting from the high electron density of the fused thiophene and aniline-like amino substituent 
on the pyridinone ring. Quinones and quinone-imines, derived from phenols and anilines, have 
been shown to be bioactivation metabolites responsible for many idiosyncratic drug toxicities in 
marketed drugs.110 
2.2 RESULTS AND DISCUSSION 
2.2.1 Synthesis of Thienopyridone 2-2 
The synthesis of 2-2 was targeted since it was the most potent inhibitor known at the time 
and could be used as a control to validate our protein assays. The synthetic route towards 2-2 has 
not been previously disclosed but the construction of the bicyclic thienopyridone scaffold via a 
tandem Curtius-rearrangement/cyclization is a well-known strategy and was used in our first 
approach towards 2-2 (Scheme 10).111  
S
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Tandem 
Curtius Rearrangement
and Cyclization
S
NH
O
NH2
2-2 2-3  
Scheme 10. Synthetic approach towards thienopyridone 2-2 using the tandem rearrangement and 
cyclization. 
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The route began with a Suzuki-Miyaura coupling of commercially available phenyl 
boronic acid and brominated thiophene 2-4 to yield aldehyde 2-5 in excellent yield (Scheme 
11).111d Regioselective bromination under acidic conditions yielded 2-6 in 98%. The 
regioselectivity arises from the unfavorable formation of the carbocation alpha to the aldehyde 
during the electrophilic aromatic substitution. The halogen offers a synthetic handle for structural 
diversification. Knoevenagel condensation onto aldehyde 2-6 produced the carboxylic acid 2-7 in 
a high yield. The three step sequence of acid chloride formation and azidation, followed by 
heating for the tandem Curtius rearrangement/cyclization gave pyridone 2-9 only in poor yield 
(ca. 23% over 3 steps) with limited scalability (<50 mg). We were interested in whether the high 
temperature was needed for the Curtius rearrangement or for the cyclization (Scheme 12). The 
reaction is thought to require three transformations: (1) the acyl azide rearranges to the vinyl 
isocyanate; (2) the trans double bond must isomerize prior to cyclization (it is possible that the 
isomerization occurs before the rearrangement); and (3) intramolecular cyclization. We thought 
that it may be more practical and safer to form the isocyanate at lower temperatures and then 
heat to 250 °C for the cyclization. However, all our attempts at low temperatures failed to 
produce any rearrangement products. Nonetheless, the synthesis of 2-2 was completed by 
nitration and then hydrogenation to yield the desired product in 9%.112  
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Scheme 11. Synthesis thienopyridone based on an established strategy.111d  
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Scheme 12. The intramolecular cyclization of 2-8 to construct the bicyclic scaffold of 2-2 
proceeds via a Curtius rearrangement, double bond isomerization, and cyclization. 
Since we could not affect the rearrangement of the acyl azide at lower temperatures, we 
searched for an alternative precursor for the isocyanate. Previous reports indicate that 
isocyanates can also be accessed from the thermal decomposition of carbamates.113 We modified 
the reaction sequence to include the formation of ethyl carbamate intermediate 2-11 (Scheme 
47 
13). With aldehyde 2-5 in hand, we carried out a Takai olefination to yield a 10:1 E/Z mixture of 
2-10.114 Purification of the olefination product proved to be difficult since iodoform and vinyl 
iodide 2-10 have similar polarities. When 2-10 was used crude in the amination reaction, the 
iodoform seemed to react and the desired product was not obtained. To address this concern, we 
switched to the Stork-Wittig olefination with phosphonium salt 2-14 and aldehyde 2-5 to give 
vinyl iodide 2-10 in 52% as an E/Z isomeric mixture of 1:1.115 The isomeric mixture is not a 
concern for the cyclization since under the high temperatures the olefin can isomerize. 
Amination attempts on purified 2-10 failed to cleanly yield vinyl carbamate 2-11. The reactions 
generally yielded a complex mixture of compounds. 
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Scheme 13. Modified synthetic route towards 2-2 without the use of azides. 
To overcome the bottleneck of synthesizing an isocyanate precursor, we decided to 
directly form the isocyanate via the primary amine 2-16 (Scheme 14).111d Additionally, not 
having a double bond in 2-16 obviated the need for the alkene isomerization at high 
temperatures. Reacting 2-16 with triphosgene formed the requisite isocyanate which underwent a 
Friedel-Crafts intramolecular cyclization with FeCl3 acting as a Lewis acid to yield lactam 2-17 
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in 71% over the two steps. The thiophene in 2-17 was brominated and then a Suzuki-Miyaura 
cross-coupling installed the phenyl ring followed by a DDQ mediated aromatization to yield 
thienopyridone 2-13. Analogous to the first route, the synthesis was completed with a nitration 
and then hydrogenation to yield 2-2 in 19%. Overall, this route is more conducive to analog 
synthesis as it allows for late-stage variations of the phenyl ring and N-substitutions (Section 
2.2.5).  
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Scheme 14. Second-generation synthesis of thienopyridone 2-2.111d  
2.2.2 Design and Synthesis of a Hybrid Analog of 2-1 and 2-2 
While the exact binding modes of BR-1 (2-1) and thienopyridione 2-2 are unknown, a 
structural overlay of the two structures showed structural similarities, suggesting some key 
interactions (Figure 16). Aligning the two carbonyl functionalities of 2-1 and 2-2 positions the 
phenyl groups in nearly identical spatial arrangements. The carbonyl groups can participate as 
hydrogen bond acceptors and the phenyl groups may be responsible for key hydrophobic 
interactions in the active site of PTP4A3. Switching the main heterocycle to a pyrimidine dione 
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scaffold in 2-19 provided a similar positioning of hydrogen bond donors and acceptors as the 
rhodanine ring, while also removing the amino group of thienopyridone and consequentially 
reducing the electron-density and potential for redox activity. 
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Figure 16. Overlay of BR-1 (2-1) and thienopyridone 2-2 for the design of the hybrid analog. 
The colored zones are planned areas of modification for SAR studies. 3D overlap modeled with 
Biovia Discovery Studio (v.16.1.0.15350). 
 SAR studies were focused on changes to zones 1–3 (Figure 16) to modulate physical 
properties and biological activity. The phenyl rings in zones 1 and 2 can be modified to improve 
the hydrophobic interactions and/or solubility of the analogs. For zone 3, the dione scaffold can 
modulated and a thioxo derivative is accessible by replacing one of the oxygen atoms with 
sulfur, similar to 2-1.  
For the hybrid analog, we envisaged constructing the amino thiophene core 2-21 via a 
Gewald reaction (Scheme 15).116 The requisite aldehyde 2-20 for the Gewald reaction would also 
introduce the desired substitution for zone 1 in 2-19. The pyrimidine dione ring 2-22 can be 
constructed by the addition of amino thiophene 2-21 to an isocyanate followed by base mediated 
cyclization and quenching with acid to establish zone 3. Subsequent bromination of the thienyl 
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pyrimidine dione 2-22 would allow for a late stage cross-coupling of 2-23 to introduce the 
desired substitution in zone 2 of 2-19.  
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Scheme 15. Synthetic strategy towards pyrimidine dione scaffold of hybrid analog design. 
Gewald thiophene synthesis with phenyl acetaldehyde (2-20) and methyl cyanoacetate (2-
24) gave amino thiophene 2-21 in 90% (Scheme 16).111d Formation of the urea adduct on the 
amino group of 2-21 with chlorosulfonylisocyanate and then cyclization under basic conditions 
followed by quenching with acid gave the cyclized product 2-22 in 57%. Once the pyrimidine 
dione ring was formed, various bromination conditions failed to provide the desired brominated 
analog 2-23 and starting material was recovered. A directed lithiation/bromination also failed. 
The difficulty of brominating the thiophene may be attributed in part due to the electron-
withdrawing nature of the fused pyrimidine dione ring as well as possible bromination of the 
nitrogen atoms. The thiophene ring in 2-22 is considerably deactivated with respect to 
electrophilic aromatic substitution. We thought that the precursor 2-21 may be a better candidate 
for bromination since the thiophene should be less deactivated.  
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Scheme 16. Attempted synthesis of pyrimidine dione analog 2-19. 
Unfortunately, attempted bromination on 2-21, with or without protecting the amino 
group, also failed. The thiophene ring was also sufficiently deactivated by the electron-
withdrawing ester functional group and the Boc group when the amino functionality is protected. 
Under mild conditions, starting material was recovered. Using stronger brominating agents or 
heat resulted in either para bromination of the phenyl ring or decomposition of the thiophene 
ring. The lone pair of the amino group is not conjugated with the C(4) of thiophene, but instead 
would delocalize to the phenyl substituent. Thus, the para position on the benzene ring was more 
activate towards the electrophilic substitution. As result, we decided to modify the route to 
eliminate the need for bromination. 
Deoxybenzoin (2-25) provides both the zone 1 and 2 substituents (Scheme 17). The 
ketone was not sufficiently reactive for a one-pot Gewald reaction. To address the lower 
reactivity, the Knoevenagel product with 2-24 was formed via Lewis acid activation of 2-25 
followed by thiophene synthesis to yield 2-26 in 87% over two steps. The combination of 
morpholine and acetic acid aids in isomerizing the Knoevenagel condensation intermediate from 
2-26int1 to 2-26int2.117 The cyano and the benzylic methylene groups in the condensation 
adduct need to be syn for the thiophene synthesis to proceed. Amino thiophene 2-26 can be 
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cyclized analogously to compound 2-22. However, this compound was not pursued any further 
once the PTP4A3 assay revealed that this series of analogs to be inactive (Section 2.2.4). 
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Scheme 17. Modified approach towards analog 2-19. 
In addition to the thieno pyrimidine dione core, we also synthesized analogs with a 2-
thioxo thieno pyrimidin-4(1H)-one core to investigate the effect of the sulfur atom on bioactivity 
(Scheme 18).111d Amino thiophenes 2-21 and 2-27 were cyclized first by addition of acylated 
isothiocyanate to give intermediates 2-28 and 2-29 in modest yield, then base-mediated 
cyclization followed by acidic treatment yielded analogs 2-30 and 2-31 in 49% and 57% 
respectively. 
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Scheme 18. Synthesis of analogs with the 2-thioxo thieno pyrimidin-4(1H)-one core.111d  
2.2.3 Photooxygenation of Thienopyridone 2-2 
 The amino-thienopyridone in 2-2 is highly electron-rich and can be a potential redox-
liability in a biological system.110 In order to decrease the electron-density in the heterocyclic 
scaffold of 2-2, we explored photooxygenation conditions for the possibility of oxidation by 
selectively introducing an oxygen atom.  While currently underutilized, photooxygenation offers 
a useful synthetic strategy to generate novel structural motifs from electron-rich moieties.118 
Recent reports demonstrated light-driven reactions in the absence of a photocatalyst or an 
additional photosensitizer. Instead, the reaction substrate itself acts a photosensitizer that is 
excited by light and drives reaction. N-heterocycles such as quinolinones and pyridones has been 
shown to be sensitive to visible light and upon excitation they can generate singlet oxygen.119 
Also, pyridones are known to trap singlet oxygen by a [4+2] cycloaddition to form pyridone 
endoperoxides.120 Thienopyridone 2-2 is bicyclic like quinolinones and contains a pyridone ring. 
Additionally, the thiophene ring and amino substituent add high electron-density, therefore, we 
had reason to believe that 2-2 was prone to photo-excitation.   
We monitored a solution of 2-2 in methanol under ambient laboratory light and we 
discovered the novel 7-iminothieno-[3,2-c]pyridine-4,6(5H,7H)-dione 2-32, but the conversion 
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was incomplete with a significant amount of 2-2 left after 2 days stirring at room temperature 
(Table 5, entry 1).111d The photooxygenation under ambient light was also attempted in 
hexafluoroisopropanol (HFIP), but only a trace amount of 2-32 was observed (Table 5, entry 2). 
In order to accelerate the reaction, we placed a 23 W CFL at a distance of 15 cm away from the 
borosilicate reaction flask and observed complete conversion within 23 h and an isolated yield of 
85% (Table 5, entry 3). This transformation was accomplished without the use of any catalysts or 
additives, and, due to its poor solubility in methanol, the isolation of 2-32 was achieved by a 
simple filtration of the reaction precipitate. The high yield is particularly noteworthy due to the 
potential for different oxidation pathways including oxidation of the thiophene ring and a ring-
contraction rearrangement of the pyridone ring.121 Compound 2-32 precipitated from the reaction 
mixture as an amorphous brown powder, but crystalline 2-32 was obtained by the slow 
evaporation of a solution in acetonitrile. The structure was confirmed by X-ray crystallography 
(Scheme 19). Larger scale synthesis required longer reaction times, presumably due to poor light 
penetration in the larger solvent volume (Table 5, entry 4). We are currently also exploring flow 
methods for this photochemical process.  
NH
O
NH2
air, visible light
S solvent, rt
NH
O
NH
S O
X-ray 
Structure2-2 2-32  
Scheme 19. Photooxygenation of 2-2.111d  
 
 
 
55 
Table 5. Screening reaction conditions for the photooxygenation of 2-2 to 2-32.111d 
entry solvent reaction scalea  light source conversion timeb  
(isolated yield) 
1 MeOH <10 mg ambient light >2 d partial conversion 
2 HFIP <10 mg ambient light 1 d trace conversion 
3 MeOH <10 mg 23 W CFLc 23 h (85%) 
4 MeOH 32.5 mg 23 W CFLc 2.5 d (77%) 
aReaction concentration was 1-1.1 mg/mL; bConversion was monitored by high resolution 
LC/MS for the disappearance of 2-2; cCompact fluorescent lamp (CFL) at a distance of 15 cm. 
 
To the best of our knowledge, the oxidized thiophene-containing scaffold has not 
previously been reported. Two literature studies of related imino-isoquinolinediones are shown 
in Scheme 20. While studying the synthesis of spiro heterocyclic compounds, the Otomasu group 
noted the spontaneous oxidation of 2-36 to 2-34 after the hydrogenation of the nitrosodione 2-36 
to the amine. The Henry group was interested in the synthesis and fluorescence properties of 2-
methyl-1-isoquinolones and found that 4-amino-2-methyl-1-isoquinolone (2-33), in contrast to 
analogous 5- or 7-amino derivatives, was converted in situ to pyridazine 2-35. They postulated 
that the dimer resulted from the condensation of 2-33 and air oxidized 2-34.  
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Scheme 20. Previously reported spontaneous oxidations of aminoquinolines, analogous to the 
transformation of 2-2 to 2-32.122 
2.2.4 Biological Evaluation of Analogs 
The biochemical activity of thienopyridone 2-2 and related analogs was evaluated in an 
in vitro assay with recombinant human PTP4A3, which was overexpressed in E. coli using His6-
tag fusion and then purified by a metal affinity column.111d The phosphatase activity was 
monitored using the artificial substrate 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) 
for 30 min at 25 °C in 40 mM Tris-HCl (pH 7.0), 2 mM EDTA, 4 mM DTT, and 75 mM NaCl 
buffer solution. The fluorescence was measured and used to calculate the percent inhibition 
relative to the maximal enzyme activity in the absence of an inhibitor and maximal inhibition in 
the presence of 2 mM Na3VO4 (Table 6). All biological evaluations were conducted by Kelley 
McQueeney, Dr. Elizabeth Sharlow, and Professor John S. Lazo at the University of Virginia 
(Charlottesville, VA). 
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Table 6. In vitro inhibition of PTP4A3 activity.111d 
entry compound IC50 [µM ± S.D.]a 
1 2-2 0.132 ± 0.003 
2 2-13 >80 
3 2-22 >240 
4 2-30 >100 
5 2-31 >100 
6 2-32 0.018 ± 0.014 
an = 3. 
The inhibitory action of 2-2 was comparable to previously reported value (Table 6).109 
The desamino analog 2-13 was ineffective at concentrations up to 80 µM, highlighting the 
significance of the 7-amino substituent. The hybrid scaffold in 2-22, 2-30, and 2-31 showed no 
inhibitory activity and these analogs can serve as negative controls in future assays. Interestingly, 
the novel analog 2-32 was nearly 10x more potent than 2-2 with an IC50 of 18 nM, making this 
imino-pyridinedione the most potent inhibitor of PTP4A3. 
Thienopyridone 2-2 and the oxidized analog 2-32 were screened against a limited panel 
of phosphatases, including members of the PTP4A family (Table 7).111d Compound 2-32 was ca. 
3x more selective towards PTP4A3 vs. PTP4A1 and PTP4A2. Moreover, the compounds showed 
little to no inhibition of other phosphatases, PTP1B and PP2A, and was significantly less potent 
towards CDC25B. Since 2-2 readily oxidizes to 2-32 (Section 2.2.3), we were interested in 
whether the thienopyridone 2-2 was oxidized in the in vitro assay. We tested the stability of 2-2 
in the assay mixture for 90 min in the presence or absence of DTT, and we did not detect by LC-
MS any quantifiable spontaneous oxidation (>5%) of 2-2 to 2-32.   
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Table 7. In vitro inhibition of the activity of a phosphatase panel by 2-2 and 2-32.111d 
 IC50 (µM ± S.D.) 
entry Phosphatase 2-2 2-32 
1 PTP4A3 0.132 ± 0.003 0.018 ± 0.014 
2 PTP1B >80 >80 
3 CDC25B 22 ± 16 2.6 ± 1.2  
4 PP2A >80 >80 
5 PTP4A1 n.d. 0.050 
6 PTP4A2 n.d. 0.52 
n.d. = not determined. 
 The activity of 2-2 and 2-32 in ovarian cancer cells lines were compared to the PTP4A3 
inhibitor BR-1 (2-1), the inactive analog 2-22, and cisplatin (Table 8).123 The human ovarian 
cancer cells were seeded, treated with a vehicle control or test compound, and incubated at 37 °C 
for 44 h. Then, the cells were incubated with alamar blue for 4 h and the cell count was 
measured. Compound 2-32 was significantly more potent than the other PTP4A3 inhibitors 2-1 
and 2-2, as well as cisplatin. Potent activity was also seen in the cisplatin resistant cell line (entry 
5).  
Table 8. Compound activity against ovarian cancer cells.123 
 EC50 (µM ± S.D.) 
entry cell line 2-1 2-2 2-32 2-22 Cisplatin 
1 SKOV3 48.3 ± 9.1 28.8 ± 2.2 4.3 ± 1.1 >50 >100 
2 OVCAR-4 48.5 ± 7.9 15.5 ± 2.4 1.5 ± 0.3 >50 30.3 ± 4.4 
3 HEYA8 >50 8.5 ± 1.3 3.2 ± 0.06 >50 n.d. 
4 A2780CW (drug sensitive) 26.4 ± 1.0 4.5 ± 0.6 0.6 ± 0.2 >50 20.7 ± 1.0 
5 A2780CP20 (cisplatin resistant) 17.3 ± 2 13.1 ± 0.6 1.1 ± 0.04 >50 >100 
n.d. = not determined. 
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2.2.5 Progress towards the Automated Synthesis of Thienopyridone Analogs 
Machine-assisted organic synthesis is an emerging field in the divergent synthesis of 
small molecules.124 In some cases, the synthesis of compounds, purification, and in vitro 
biological evaluation is automated in sequence to allow for the rapid screening of compounds for 
biological activity.125 However, relative to conventional synthesis, automated synthesis remains 
in its infancy with regard to reaction efficiency, scope, and scale. As a result, this field provides a 
vast opportunity for development of new methods and expansion of its application in small 
molecule synthesis. 
We are interested in expanding the SAR of both 2-2 and 2-32 to gain a better 
understanding of the physical attributes responsible for the observed bioactivity and to expand on 
the reaction scope of the photooxygenation. The thienopyridone scaffold of 2-2 allows for a 
divergent multi-step synthesis of analogs featuring a variety of useful transformations such as 
cross-couplings, halogenations, and alkylations that would be suitable for automated synthesis 
(Scheme 21). Therefore, we pursued a collaboration with Lilly and their Open Innovation Drug 
Discovery (OIDD) program and were granted access to their Automated Synthesis Lab (ASL).126 
The program features a globally accessible, remote-controlled automated chemical synthesis lab 
that allows for real-time monitoring and manipulation of reaction parameters by remote users. 
Among its many features, the system is enabled with conventional and microwave heating, 
liquid-handling abilities, workup stations, cameras for visual inspection, LC/MS for reaction 
monitoring, and solvent evaporation.   
The synthetic route was modeled on the improved synthesis of 2-2 (Scheme 14). Starting 
with the bicyclic 2-18, a Suzuki-Miyaura or Sonogashira cross-coupling attaches the cyclic or 
alkynyl substituent in the R1 position of 2-38. Then, N-alkylation provides the R2 substitution in 
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2-39 followed by aromatization with DDQ to yield thienopyridone 2-40. Unlike the previous 
synthetic routes (Section 2.2.1), the use of corrosive nitric acid is avoided on the automated 
system. Instead, halogenation of 2-40 provides 2-41, the precursor for the transition-metal 
catalyzed amination reactions. Once the synthesis of 2-37 is completed, the analogs will be 
subjected to the photooxygenation conditions to explore the scope of the transformation. Mainly, 
we want to explore the impact of the R3 and R4 substitutions on the oxidation of 2-37 to the 2-32 
imine dione scaffold.  
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Scheme 21. Synthetic route for the automated synthesis of thienopyridone 2-37. 
Procedural workflows were designed for each transformation providing step-by-step 
instructions to the robot (Figure 17). Once the reaction instructions were submitted, a chemist 
weighed out the requested reactants, reagents, and solvents into a reaction vessel. Deoxygenation 
with an inert gas such as argon and nitrogen was conducted upon request for air sensitive 
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reactions involving transition metals. The reaction vessel was then placed on the automated 
system and the robot started to carry out the instructions. Cameras equipped on the system 
provided snapshots of the vessels for visual inspection. The vessel was placed in incubation 
under the requested temperature for a defined amount of time on either a conventional heating 
plate or in a microwave reactor. Reaction progress was monitored by periodic sampling of the 
crude reaction mixture for LC/MS analysis. Then, the crude mixture was quenched as needed 
and filtered. Volatile components were evaporated and the crude weight was measured. Based on 
the crude LC/MS result, the sample was either sent for additional purification via mass-guided 
HPLC in the Automated Purification Lab (APL) or sent to storage for use in the next reaction. 
 
Figure 17. An abbreviated representative of the workflow instructions for the automated 
synthesis of analogs.127 
 The reaction workflows were tailored based on our procedures for the synthesis of 2-2 
(Scheme 14), to first provide cross-coupling product 2-38 which was used crude in the oxidation 
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step to yield 2-40 in modest yield over two steps (Scheme 22 and 24). In automated systems, the 
reaction components must remain in solution to allow for the flow of the mixtures from one 
station to another, such as moving from the incubation station to the quench station. This 
requirement proved especially challenging for compounds 2-40 due to their poor solubility in 
common organic solvents. The low solubility may have in part contributed to the modest isolated 
yields (26-45%), despite complete conversion of reactants to products as observed by LC/MS. 
Bromination of 2-13 and 2-40e gave access to halides 2-41a,e for the subsequent transition-metal 
catalyzed amination reactions (Table 9).  
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Scheme 22. Progress towards the automated synthesis of thienopyridone analogs 2-37. 
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Scheme 23. Progress towards the automated synthesis of N-alkylated thienopyridone analogs 2-
37. 
 
 Our initial attempts to install the amines by Pd and Cu catalysis were unsuccessful (Table 
9). In most cases, starting material or dehalogenated starting material was recovered. We 
considered the possibility that the pyridone moiety and the sulfur atom in the thiophene ring may 
deactivate the transition metals. To mask the pyridone moiety, 2-41a was protected with a benzyl 
group to yield 2-42a in 49% (Scheme 22) but the coupling attempts were still unsuccessful 
(entries 5 and 6)). We are currently screening more coupling conditions to troubleshoot this final 
reaction and complete the synthesis of 2-37. 
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Table 9. Attempted amination reaction in the Lilly automated synthesis lab. 
 
entry halide amine (equiv.) reaction conditions (equiv.) Resulta 
1 2-41a piperidine (1.5) Pd2dba3 (3 mol%) 
Davephos (9 mol%), NaOt-Bu (3) 
toluene, 100 °C, 20 h 
No pdt. found 
2 2-41a CF3CONH2 (1.5) CuI (5 mol%) 
Dimethylethylenediamine (10 mol%) 
K2CO3 (4) 
dioxane, µW 125 °C, 2 h 
RSM 
3 2-41a CF3CONH2 (1.5) CuI (10 mol%) 
Dimethylcyclohexyldiamine (20 mol%) 
K2CO3 (4) 
dioxane/H2O, µW 125 °C, 2 h 
des-Br SM 
4 2-41a CF3CONH2 (1.5) CuI (10 mol%) 
Dimethylcyclohexyldiamine (20 mol%) 
K2CO3 (4) 
dioxane, 90 °C, 16 h 
No pdt. found 
5 2-42a piperidine (1.5) Pd-175 (5 mol%) 
Brettphos (5 mol%), NaOt-Bu (2) 
THF, 80 °C, 12 h 
SM + des-Br SM 
6 2-42a CF3CONH2 (3) CuI (20 mol%) 
Dimethylcyclohexyldiamine (40 mol%) 
KOt-Bu (4) 
toluene, 100 °C, 20 h 
RSM 
7 2-41e (CH3)2NH (1.5) t-BuXPhos Pd G1 (2 mol%) 
LiHMDS (1.5) 
THF, rt, 3 h 
SM 
2.3 CONCLUSION 
 Phosphatases provide an opportunity for the development of novel inhibitors. With the 
propensity of malignancies to develop resistance to kinase inhibitors, phosphatases can offer 
options for alternative therapies. The current inhibitors of PTP4A are limited by selectivity, 
potency, and structural alerts. We designed a hybrid scaffold based on the structural features of 
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known PTP4A3 inhibitors, BR-1 (2-1) and thienopyridone 2-2. Unfortunately, this scaffold 
proved ineffective against PTP4A3. Interestingly, photooxygenation of 2-2 yielded the novel 
imino-pyridine dione 2-32 that was a more potent inhibitor of PTP4A3. This compound showed 
selectivity towards PTP4A3 over other phosphatases and was active against human ovarian 
cancer cells. We are currently completing the automated synthesis of relevant analogs to explore 
the SAR of 2-2 and 2-32 and expand on the scope of the photooxygenation of amino-
thienopyridones.  
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3.0 EXPERIMENTAL PART 
3.1 GENERAL EXPERIMENTAL 
 All air-sensitive reactions were performed under an N2 or Ar atmosphere. Reactions 
carried out at temperatures above rt employed an oil bath, Lab Armor BeadsTM (SKU # 42370), 
or a microwave reactor, as indicated. All microwave reactions were performed in sealed vials in 
a Biotage Initiator reactor (power range: 0 – 400 W from a magnetron at 2.45 GHz, temperature 
range: 40 – 250 °C, and pressure range: 0 – 20 bar). EtOH was stored over 4Å molecular sieves. 
1,4-Dioxane and H2O were deoxygenated by the freeze-pump-thaw technique or by sparging 
with Ar for 20 – 60 min immediately before use. THF was distilled over sodium/benzophenone 
ketyl. Et3N was stored over KOH. All commercial reagents were used as received. Concentrating 
under reduced pressure refers to removing solvents by the use of a rotary evaporator connected 
to a PIAB Lab Vac H40. 
 Reactions were monitored by thin layer chromatography analysis (EMD, pre-coated silica 
gel 60 F254 plates, 250 µm layer thickness) and visualization was accomplished with a 254 nm or 
365 nm UV light and by staining with a KMnO4 solution (3 g of KMnO4 and 4 g of K2CO3 in 
200 mL of a 5% NaOH solution) when needed. Flash chromatography on SiO2 (Silicycle, Silia-P 
Flash, or SiliaFlash® P60; 40-63 μm) was used to purify the crude reaction mixtures where 
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indicated. All products were placed under high vacuum (0.5 – 4 mmHg) to remove trace 
solvents. 
 Melting points were determined using Laboratory Devices Mel-Temp II in open capillary 
tubes and are uncorrected. Infrared spectra were obtained from neat solids or oils on a Perkin 
Elmer® Spectrum 100 FT-IR or Smiths Detection IdentifyIR FT-IR spectrometer. High-
resolution mass spectra were obtained on a Micromass UK Limited, Q-TOF Ultima API or a 
Thermo Scientific Exactive Orbitrap LC-MS. Purities of final products were determined sing 
Agilent Technologies 385-ELSD. ELSD conditions: evaporator and nebulizer set at 45 °C; gas 
flow set at 1.80 standard liter / min; X Bridge BEH C18 2.5 µM; 2.1 x 50 mm XP column. 
 1H NMR spectra were obtained on a Bruker Avance at 300 MHz, 400 MHz, 500 MHz, or 
600 MHz in CDCl3, (CD3)2SO, THF-d8, or CD3OD. Chemical shifts (δ) were reported in parts 
per million with the residual solvent peak used as an internal standard δ 1H / 13C (solvent): 
7.26/77.16 (CDCl3); 2.50/39.52 ((CD3)2SO); 1.72 and 3.58 / 67.21 and 25.31 (THF-d8); 
3.31/49.00 (CD3OD). 1H NMR spectra were obtained and are tabulated as follows: chemical 
shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad 
singlet), number of protons, and coupling constant(s). 13C NMR spectra were recorded using a 
proton-decoupled pulse sequence run at 100 MHz, 125 MHz, or 150 MHz and are tabulated by 
observed peaks. 
Supercritical fluid chromatography (SFC) semi-prep purification used a Mettler Toledo 
AG - Berger SFC™ MiniGram instrument. Sample preparation involved dissolving the analyte 
(10 mg/mL) in HPLC-grade MeOH and filtering with a 13 mm Millex® Syringe Filter (0.45 µm 
pore size). Separation was accomplished with a SiO2 column (250 x 10 mm) at 100 bar pressure 
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with a detection wavelength of 220 nm, an oven temp. of 35 °C, an evaporator temp. of 27 °C, a 
trimmer temp. of 27 °C and using MeOH as a modifier under isocratic conditions. 
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3.2 CHAPTER 1 EXPERIMENTAL PART 
Suzuki-Miyaura Cross-Coupling48 
General Procedure A. Brominated heterocycle (1 equiv.) was added to a stirred mixture of 
boronic acid (2.1 – 2.3 equiv.), Pd2dba3 (1 mol%), t-Bu3P (6 mol%), and Na2CO3 (2.3 equiv.) in 
deoxygenated 1,4-dioxane/H2O (2:1, 0.1 M – 0.2 M) in a microwave vial under N2 or Ar. The 
reaction mixture was sealed and heated to 70 °C for 30 min or 60 min in a microwave reactor. 
Upon completion, the reaction mixture was allowed to cool to rt and purified as indicated.  
General Procedure B. Brominated heterocycle (1 equiv.) was added to a stirred mixture of 
boronic acid (3.5 equiv.), Pd2dba3 (2 mol%), t-Bu3P (10 mol%), and Na2CO3 (2.3 equiv.) in 
deoxygenated 1,4-dioxane/H2O (2:1, 0.1 M – 0.2 M) in a microwave vial under N2 or Ar. The 
reaction mixture was sealed and heated to 70 °C for 60 min in a microwave reactor. Upon 
completion, the reaction mixture was allowed to cool to rt and purified as indicated.  
C-H Activation / Cross-Coupling48 
General Procedure C. Brominated heterocycle (1 equiv.) was added to a stirred mixture of ethyl 
oxazole-4-carboxylate (1-20) (2.1 equiv.), Pd(OAc)2 (5 mol%), CyJohnPhos (10 mol%), and 
Cs2CO3 (3.5 equiv.) in 1,4-dioxane (2 mL) in a vial. The solution was flushed with Ar, sealed, 
and stirred at 110 °C in an oil bath for 22 h. The reaction mixture was allowed to cool to rt and 
purified as indicated. 
Aldehyde and Ester Reduction48 
General Procedure D. NaBH4 (3 – 4 equiv.) was added to a suspension of aldehyde (1 equiv.) 
in THF/MeOH (4:1, 0.1 M – 0.2 M). The reaction mixture was stirred at rt until TLC analysis 
indicated the complete consumption of starting material. The solution was concentrated under 
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reduced pressure, diluted with water, and extracted with EtOAc. The combined organic layers 
were dried (MgSO4 or Na2SO4), filtered, and concentrated under reduced pressure.  
General Procedure E. LiAlH4 in diethyl ether (1 M solution, 2 equiv.) was added slowly to a 
stirred solution of ester (1 equiv.) in CH2Cl2 (0.1 – 0.2 M) at 0 °C under N2 or Ar. The reaction 
mixture was stirred for 1 h – 1.5 h at the same temperature, quenched and purified as indicated.  
 
O
O O CHOOHC
 
1-14a 
[2,2':5',2''-Terfuran]-5,5''-dicarbaldehyde (1-14a).46b,47a,48 Prepared by general procedure A 
with 2,5-dibromofuran (1-12a) (0.48 mmol) and (5-formylfuran-2-yl)boronic acid (1-13a). The 
reaction mixture was diluted with water and the precipitate was filtered. The crude precipitate 
was purified by chromatography on SiO2 (2 – 5% MeOH/CH2Cl2) to yield 1-14a (0.062 g, 51%) 
as an orange solid: Mp > 215 °C (dec., acetone); IR (ATR) 3141, 3115, 2835, 1661, 1473, 1265, 
958, 767 cm-1; 1H NMR ((CD3)2SO, 400 MHz) δ 9.64 (s, 2 H), 7.70 (d, 2 H, J = 4.0 Hz), 7.30 (s, 
2 H), 7.20 (d, 2 H, J = 3.6 Hz) ; 13C NMR ((CD3)2SO, 100 MHz, 60 °C) δ 177.3, 151.7, 148.6, 
144.9, 124.1, 111.9, 109.3; HRMS (ESI+) m/z calcd for C14H9O5 (M+H)+ 257.0444, found 
257.0436. 
 
S
O O CHOOHC
 
1-14b 
5,5'-(Thiophene-2,5-diyl)bis(furan-2-carbaldehyde) (1-14b).46b,48 Prepared by general 
procedure A with 2,5-dibromothiophene (1-12b) (1.8 mmol) and 1-13a. The precipitate was 
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filtered, and the residue was rinsed with water (2 x 15 mL) and washed with diethyl ether (2 x 15 
mL) to yield 1-14b (0.427 g, 88%) as a yellow solid: Mp > 250 °C (dec., acetone); IR (ATR) 
3115, 3075, 2850, 1655, 1477, 1394, 1263, 1027 cm-1; 1H NMR ((CD3)2SO, 400 MHz) δ 9.60 (s, 
2 H), 7.78 (s, 2 H), 7.69 (d, 2 H, J = 3.6 Hz), 7.27 (d, 2 H, J = 4.0 Hz); 13C NMR ((CD3)2SO, 125 
MHz, 60 °C) δ 177.1, 152.4, 151.4, 132.0, 127.5, 124.5, 109.2; HRMS (ESI+) m/z calcd for 
C14H9O4S (M+H)+ 273.0216, found 273.0212. 
 
Se
O O CHOOHC
 
1-14c 
5,5'-(Selenophene-2,5-diyl)bis(furan-2-carbaldehyde) (1-14c).47b,48 Prepared by general 
procedure A with 2,5-dibromoselenophene (1-12c) (0.580 mmol) and 1-13a. The precipitate was 
filtered, and the residue was rinsed with water (2 x 15 mL) and washed with diethyl ether (2 x 10 
mL) to yield 1-14c (0.172 g, 93%) as a yellow solid: Mp > 215 °C (dec., MeOH); IR (ATR) 
3114, 3049, 2842, 1655, 1478, 1391, 1261, 1025 cm-1; 1H NMR ((CD3)2SO, 400 MHz) δ 9.58 (s, 
2 H), 7.93 (s, 2 H), 7.67 (d, 2 H, J = 3.6 Hz), 7.27 (d, 2 H, J = 3.6 Hz); 13C NMR ((CD3)2SO, 125 
MHz, 60 °C) δ 177.1, 154.4, 151.4, 136.6, 129.5, 124.7, 109.0; HRMS (ESI+) m/z calcd for 
C14H9O4Se (M+H)+ 320.9661, found 320.9652. ELSD purity = 100%. 
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CHO  
1-14d 
5,5'-(Thiophene-3,4-diyl)bis(furan-2-carbaldehyde) (1-14d).48 Prepared by general procedure 
B with 3,4-dibromothiophene (1-12d) (0.54 mmol) and 1-13a. The precipitate was filtered, 
rinsed with water, and purified by chromatography on SiO2 (1% MeOH/CH2Cl2) to yield 1-14d 
(0.138 g, 93%) as a pale yellow solid: Mp 144-147 °C (CH2Cl2); IR (ATR) 3130, 3083, 2851, 
1658, 1525 cm-1; 1H NMR (CDCl3, 500 MHz) δ 9.63 (s, 2 H), 7.80 (s, 2 H), 7.29 (d, 2H, J = 3.5 
Hz), 6.60 (d, 2 H, J = 3.5 Hz); 13C NMR (CDCl3, 100 MHz) δ 177.3, 154.2, 152.0, 129.0, 128.2, 
123.1, 110.7; HRMS (ESI+) m/z calcd for C14H8O4NaS (M+Na)+ 295.0036, found 295.0034.  
 
S
O
OHC
O
CHO  
1-14e 
5,5'-(2,5-Dimethylthiophene-3,4-diyl)bis(furan-2-carbaldehyde) (1-14e).48 Prepared by 
general procedure B with 2,5-dimethyl-3,4-dibromothiophene (1-12e) (0.741 mmol) and 1-13a. 
The reaction mixture was allowed to cool to rt and diluted with water (5 mL). The precipitate 
was filtered through Celite and washed with water (30 mL). The residue was dissolved in 
CH2Cl2, filtered, concentrated, and purified by chromatography on SiO2 (0 – 50% 
EtOAc/hexanes) to yield 1-14e (0.176 g, 79%) as a light orange solid: Mp 140.1-141.2 °C 
(EtOAc); IR (ATR) 3113, 2848, 1659, 1526, 1387, 1029, 969, 749 cm-1; 1H NMR ((CD3)2SO, 
500 MHz) δ 9.50 (s, 2 H), 7.58 (d, 2 H, J = 4.0 Hz), 6.57 (d, 2 H, J = 3.5 Hz), 2.48 (s, 6 H); 13C 
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NMR ((CD3)2SO, 125 MHz) δ 177.7, 153.3, 151.3, 137.8, 125.7, 124.1, 111.9, 14.1; HRMS 
(ESI+) m/z calcd for C16H12O4NaS (M+Na)+ 323.0349, found 323.0345. 
 
S
O O CHOOHC
 
1-14f 
5,5'-(Thiophene-2,4-diyl)bis(furan-2-carbaldehyde) (1-14f).48 Prepared by general procedure 
B with 2,4-dibromothiophene (1-12f) (0.89 mmol) and 1-13a. The reaction mixture was diluted 
with water (5 mL) and the precipitate was collected on Celite, rinsed with water (20 mL), washed 
off the filter with CH2Cl2, and concentrated under reduced pressure. The residue was purified by 
chromatography on SiO2 (0 – 20% CH2Cl2/EtOAc then EtOAc) to yield 1-14f (0.146 g, 60%) as 
a light orange solid: Mp >170 °C (dec., CH2Cl2); IR (ATR) 3074, 2816, 1663, 1465, 768 cm-1; 
1H NMR (CDCl3, 400 MHz) δ 9.65 (2s, 2 H), 7.83 (d, 1 H, J = 1.6 Hz), 7.81 (d, 1 H, J = 1.2 Hz), 
7.32 (d, 1 H, J = 3.6 Hz), 7.31 (d, 1 H, J = 3.6 Hz), 6.76 (d, 1 H, J = 3.6 Hz), 6.74 (d, 1 H, J = 3.6 
Hz); 13C NMR ((CD3)2SO, 100 MHz, 60 °C) δ 177.3 (2 C), 153.9, 152.6, 151.3, 151.2, 132.4, 
131.2, 125.3, 124.7, 124.6, 123.7, 108.9, 108.8; HRMS (ESI+) m/z calcd for C14H9O4S (M+H)+ 
273.0216, found 273.0213. 
 
O
S O CHOOHC
 
1-14g 
5'-(5-Formylthiophen-2-yl)-[2,2'-bifuran]-5-carbaldehyde (1-14g).22d Prepared by general 
procedure A with 1-16 (0.36 mmol) and 1-13a. The precipitate was filtered and the residue was 
rinsed with water (10 mL), washed with diethyl ether (10 mL), and dried (Na2SO4) to yield 1-14g 
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(0.081 g, 78% (>95% purity by 1H NMR)) as a dark brown solid: 1H NMR (CDCl3, 400 MHz) δ 
9.91 (s, 1 H), 9.66 (s, 1 H), 7.72 (d, 1 H, J = 4.0 Hz), 7.43 (d, 1 H, J = 4.0 Hz), 7.34 (d, 1 H, J = 
4.0 Hz), 7.01 (d, 1 H, J = 3.6 Hz), 6.88-6.85 (m, 2 H). The product was passed through a SiO2 
plug using EtOAc before reduction to 1-15g. 
 
O
S S CHOOHC
 
1-14h 
5,5'-(Furan-2,5-diyl)bis(thiophene-2-carbaldehyde) (1-14h).22d Prepared by general procedure 
A with 1-16 (0.408 mmol) and 1-13c. The reaction mixture was diluted with water (10 mL) and 
the precipitate was filtered. The residue was rinsed with water (25 mL) to yield 1-14h (0.107 g, 
91%) as a brown glossy solid: 1H NMR ((CD3)2SO, 300 MHz) δ 9.93 (s, 2 H), 8.05 (d, 2 H, J = 
4.2 Hz), 7.71 (d, 2 H, J = 4.2 Hz), 7.34 (s, 2 H). 
 
O
O O
HO OH
 
1-15a 
[2,2':5',2''-Terfuran]-5,5''-diyldimethanol (1-15a).22d,46b,47a,48 Prepared by general procedure D 
with 1-14a (0.11 mmol) to yield 1-15a (0.028 g, 92%) as a tan solid: Mp > 155 °C (dec., 
acetone); IR (ATR) 3283, 2915 1457, 1211, 999, 776 cm-1; 1H NMR (CD3OD, 500 MHz) δ 6.66 
(s, 2 H), 6.60 (d, 2 H, J = 3.0 Hz), 6.41 (d, 2 H, J = 3.5 Hz), 4.56 (s, 4 H); 13C NMR (CD3OD, 
100 MHz) δ 155.8, 147.2, 147.0, 110.4, 107.8, 107.1, 57.3; HRMS (ESI+) m/z calcd for 
C14H11O4 (M-OH)+ 243.0652, found 243.0645. 
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1-15b 
(Thiophene-2,5-diylbis(furan-5,2-diyl))dimethanol (1-15b).22d,46b,48 Prepared by general 
procedure D with 1-14b (1.57 mmol) to yield 1-15b (0.400 g, 94%) as a tan solid: Mp 102-104 
°C (EtOAc); IR (ATR) 3276, 2924, 1441, 1062, 991, 783 cm-1; 1H NMR ((CD3)2SO, 300 MHz) 
δ 7.29 (s, 2 H), 6.72 (d, 2 H, J = 3.3 Hz), 6.41 (d, 2 H, J = 3.0 Hz), 5.29 (t, 2 H, J = 5.1 Hz), 4.42 
(d, 4 H, J = 5.7 Hz); 13C NMR ((CD3)2SO, 125 MHz) δ 155.2, 147.4, 131.2, 123.3, 109.4, 106.6, 
55.6; HRMS (ESI+) m/z calcd for C14H11O3S (M-OH)+ 259.0423, found 259.0420. ELSD purity 
= 99%.  
 
Se
O O
HO OH
 
1-15c 
(Selenophene-2,5-diylbis(furan-5,2-diyl))dimethanol (1-15c).47b,48 Prepared by general 
procedure D with 1-14c (1.50 mmol) to yield 1-15c (0.441 g, 91%) as a yellow solid: Mp > 108 
°C (dec., EtOAc); IR (ATR) 3327, 2925, 1450, 1183, 1051, 1015, 988 cm-1; 1H NMR 
((CD3)2SO, 300 MHz) δ 7.44 (s, 2 H), 6.74 (d, 2 H, J = 3.0 Hz), 6.40 (d, 2 H, J = 3.3 Hz), 5.29 (t, 
2 H, J = 5.7 Hz), 4.41 (d, 4 H, J = 5.7 Hz); 13C NMR ((CD3)2SO, 125 MHz) δ 155.3, 149.4, 
135.5, 125.1, 109.7, 106.5, 55.6; HRMS (ESI+) m/z calcd for C14H11O3Se (M-OH)+ 306.9868, 
found 306.9864. ELSD purity = 99%. 
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1-15d 
(Thiophene-3,4-diylbis(furan-5,2-diyl))dimethanol (1-15d).48 Prepared by general procedure 
D with 1-14d (0.429 mmol). Extraction gave a crude oil that was purified by chromatography on 
SiO2 (CH2Cl2 then EtOAc). The oil was dissolved in CH2Cl2 (1 mL), dried (Na2SO4), and 
concentrated to yield 1-15d (0.107 g, 90%) as a yellow viscous oil: IR (ATR) 3323, 2934, 1602, 
1450, 1007, 788 cm-1; 1H NMR ((CD3)2SO, 400 MHz) δ 7.73 (s, 2 H), 6.33 (d, 2 H, J = 2.8 Hz), 
6.25 (d, 2 H, J = 3.2 Hz), 5.26 (t, 2 H, J = 5.6 Hz), 4.41 (d, 4 H, J = 5.2 Hz); 13C NMR (CDCl3, 
100 MHz) δ 153.4, 149.6, 130.5, 124.5, 109.6, 108.4, 57.6; HRMS (ESI+) m/z calcd for 
C14H11O3S (M-OH)+ 259.0423, found 259.0423. ELSD purity = 100%. 
 
S
O O
HO OH
 
1-15e 
((2,5-Dimethylthiophene-3,4-diyl)bis(furan-5,2-diyl))dimethanol (1-15e).48 Prepared by 
general procedure D with 1-14e (0.390 mmol) to yield 1-15e (0.115 g, 97%) as a viscous yellow 
oil: IR (ATR) 3374, 2934, 1007, 790, 727 cm-1; 1H NMR (CDCl3, 400 MHz) δ 6.30 (d, 2 H, J = 
3.2 Hz), 6.16 (d, 2 H, J = 3.2 Hz), 4.47 (s, 4 H), 2.68 (br s, 2 H), 2.44 (s, 6 H); 13C NMR (CDCl3, 
100 MHz) δ 152.9, 149.4, 134.4, 127.9, 109.4, 109.1, 57.3, 14.4; HRMS (ESI+) m/z calcd for 
C16H15O3S (M-OH)+ 287.0736, found 287.0736. ELSD purity = 99%. 
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1-15f 
(Thiophene-2,4-diylbis(furan-5,2-diyl))dimethanol (1-15f).48 Prepared by general procedure D 
with 1-14f (0.441 mmol) to yield 1-15f (0.110 g, 90%) as a light yellow solid: Mp 108.2-109.6 
°C (EtOAc); IR (ATR) 3379, 3256, 2934, 1441, 1007, 788 cm-1; 1H NMR (CD3OD, 400 MHz) δ 
7.53 (d, 1 H, J = 1.2 Hz), 7.46 (d, 1 H, J = 1.6 Hz), 6.59 (d, 1 H, J = 3.2 Hz), 6.56 (d, 1 H, J = 3.2 
Hz), 6.39 (d, 1 H, J = 3.2 Hz), 6.37 (d, 1 H, J = 3.2 Hz), 4.55 (s, 4 H); 13C NMR (CD3OD, 100 
MHz) δ 155.6, 155.1, 151.7, 150.1, 135.7, 134.4, 120.7, 118.4, 110.7, 110.3, 107.2, 106.9, 57.5, 
57.4; HRMS (ESI+) m/z calcd for C14H11O3S (M-OH)+ 259.0423, found 259.0420. ELSD purity 
= 100%. 
 
O
S O
HO OH
 
1-15g 
(5-(5'-(Hydroxymethyl)-[2,2'-bifuran]-5-yl)thiophen-2-yl)methanol (1-15g).22d,48 Prepared by 
general procedure D with 1-14g (0.173 mmol) to yield 1-15g (0.043 g, 90%) as a brown solid: 
Mp 105.5-107.8 °C (EtOAc); IR (ATR) 3341, 2933, 1450, 1003, 768 cm-1; 1H NMR (CD3OD, 
400 MHz) δ 7.19 (d, 1 H, J = 3.6 Hz), 6.95 (d, 1 H, J = 3.6 Hz), 6.64-6.62 (m, 2 H), 6.59 (d, 1 H, 
J = 3.2 Hz), 6.41 (d, 1 H, J = 3.2 Hz), 4.74 (s, 2 H), 4.56 (s, 2 H); 13C NMR (CD3OD, 100 MHz) 
δ 155.8, 150.2, 147.2, 146.8, 145.7, 134.0, 126.8, 123.5, 110.4, 108.2, 107.7, 107.0, 60.0, 57.3; 
HRMS (ESI+) m/z calcd for C14H11O3S (M-OH)+ 259.0423, found 259.0415. ELSD purity = 
100%. 
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1-1 
(Furan-2,5-diylbis(thiophene-5,2-diyl))dimethanol (1-1).22d Prepared by general procedure D 
with 1-14h (0.100 mmol), under modified purification conditions. After the reaction was 
completed, the mixture was concentrated, diluted with water (15 mL), and extracted with EtOAc 
(15 mL). The organic layer was sequentially washed with a solution of cysteine (0.750 g in 15 
mL water), a solution of cysteine and Na2S2O3 pentahydrate (0.750 g of each solid in 15 mL 
water), and water (15 mL). The organic layer was then dried (Na2SO4) and concentrated to yield 
1-1 (0.030 g, 99%) as a yellow solid: 1H NMR ((CD3)2SO, 400 MHz) δ 7.23 (d, 2 H, J = 3.6 Hz), 
6.95 (d, 2 H, J = 3.6 Hz), 6.78 (s, 2 H), 5.55 (t, 2 H, J = 5.6 Hz), 4.64 (d, 4 H, J = 5.6 Hz); 13C 
NMR ((CD3)2SO, 100 MHz) δ 147.9, 146.0, 131.1, 124.8, 122.6, 107.4, 58.3. 
 
O
SOHC Br
 
1-16 
5-(5-Bromofuran-2-yl)thiophene-2-carbaldehyde (1-16).22d,48 Intermediate 5-(furan-2-
yl)thiophene-2-carbaldehyde was prepared by general procedure A with 5-bromothiophene-2-
carbaldehyde (1-12g) (0.925 mmol) and furan-2-ylboronic acid (1-13b). The reaction mixture 
was diluted with water (10 mL) and extracted with EtOAc (3 x 15 mL). The combined organic 
layers were dried (MgSO4), filtered, and concentrated under reduced pressure to yield a red oil. 
The oil was passed through a short SiO2 column (CH2Cl2) to yield crude 5-(furan-2-
yl)thiophene-2-carbaldehyde (0.165 g) as a red oil. NBS (0.304 g, 1.71 mmol) was added slowly 
at -15 °C to a stirred solution of benzoyl peroxide (0.044 g, 0.18 mmol) and crude aldehyde 
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(0.165 g) in toluene (5 mL). The solution was stirred for 4 h at -15 °C. More NBS (0.125 g) was 
added and the reaction mixture was stirred for an additional 2 h at -15 °C. The reaction mixture 
was purified by chromatography on SiO2 (0 – 20% CH2Cl2/hexanes) to yield 1-16 (0.145 g, 61% 
over two steps) as a bright yellow solid: 1H NMR (CDCl3, 300 MHz) δ 9.89 (s, 1 H), 7.68 (d, 1 
H, J = 4.2 Hz), 7.32 (d, 1 H, J = 3.9 Hz), 6.69 (d, 1 H, J = 3.6 Hz), 6.43 (d, 1 H, J = 3.6 Hz). 
 
S
O
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O
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1-19a 
Diethyl 2,2'-(thiophene-2,5-diyl)bis(oxazole-4-carboxylate) (1-19a).48 Prepared by general 
procedure C with 1-12b (1.06 mmol). The reaction mixture was diluted with CH2Cl2, and filtered 
through a pad of Celite. The filtrate was concentrated under reduced pressure, washed with 
hexanes, and filtered to yield a rust colored solid. The solid was dissolved in EtOAc (30 mL) and 
washed with aq. 10% sodium acetate. The organic layer was dried (MgSO4) and concentrated. 
The residue was passed through a SiO2 plug with CH2Cl2 followed by EtOAc to yield 1-19a 
(0.198 g, 52%) as a bright orange solid: Mp 204.3-206.1 °C (CH2Cl2/EtOAc); IR (ATR) 3133, 
2934, 1722, 1588, 1146 cm-1; 1H NMR (CDCl3, 300 MHz) δ 8.25 (s, 2 H), 7.79 (s, 2 H), 4.43 (q, 
4 H, J = 7.2 Hz), 1.41 (t, 6 H, J = 6.9 Hz); 13C NMR (CDCl3, 125 MHz) δ 161.0, 157.7, 143.7, 
135.2, 131.8, 129.8, 61.6, 14.4; HRMS (ESI+) m/z calcd for C16H15O6N2S (M+H)+ 363.0645, 
found 363.0644. 
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1-19b 
Diethyl 2,2'-(selenophene-2,5-diyl)bis(oxazole-4-carboxylate) (1-19b).48 Prepared by general 
procedure C with 1-12c (0.837 mmol). The reaction mixture was diluted with CH2Cl2 and 
filtered through a pad of Celite. The filtrate was concentrated under reduced pressure, triturated 
with hexanes (3 x 15 mL), and filtered to yield 1-19b (0.153 g, 45%) as a brown solid: Mp 
171.5-173.5 °C (MeOH); IR (ATR) 3131, 2975, 2934, 1720, 1312, 1141, 1105 cm-1; 1H NMR 
(CDCl3, 500 MHz) δ 8.23 (s, 2 H), 7.97 (s, 2 H), 4.43 (q, 4 H, J = 7.0 Hz), 1.41 (t, 6H , J = 7.0 
Hz); 13C NMR (CDCl3, 125 MHz) δ 161.1, 159.4, 143.8, 136.5, 135.4, 131.9, 61.7, 14.5; HRMS 
(ESI+) m/z calcd for C16H15O6N2Se (M+H)+ 411.0090, found 411.0087.      
 
S
O
N N
O
HO OH  
1-21a 
(Thiophene-2,5-diylbis(oxazole-2,4-diyl))dimethanol (1-21a).48 Prepared by general procedure 
E with 1-19a (0.20 mmol). Saturated aqueous Rochelle's salt (1 mL) was added to the reaction 
solution and the mixture was stirred for 1 h at 0 ºC and extracted with CH2Cl2/isopropanol (3:1). 
The organic layers were combined, dried (MgSO4), and concentrated. The residue was filtered 
through Celite with MeOH and concentrated to yield 1-21a (0.044 g, 78%) as a yellow solid: Mp 
> 175 °C (dec., MeOH); IR (ATR) 3314, 3090, 2464, 1590, 1372, 982 cm-1; 1H NMR (CD3OD, 
500 MHz) δ 7.86 (t, 2 H, J = 1.0 Hz), 7.71 (s, 2 H), 4.57 (d, 4 H, J = 1.0 Hz); 13C NMR (CD3OD, 
81 
125 MHz) δ 158.5, 144.0, 137.4, 133.0, 129.8, 57.1; HRMS (ESI+) m/z calcd for C12H11O4N2S 
(M+H)+ 279.0434, found 279.0428. ELSD purity = 100%. 
 
Se
O
N N
O
HO OH  
1-21b 
(Selenophene-2,5-diylbis(oxazole-2,4-diyl))dimethanol (1-21b).48 Prepared by general 
procedure E with 1-19b (0.575 mmol). Water (44 μL), 15% NaOH solution (44 μL), and water 
(136 μL) were added sequentially to the reaction mixture at 0 ºC. The mixture was stirred for 1 h, 
dried (MgSO4) and filtered through Celite. The filter cake was washed with CH2Cl2 (3 x 10 mL). 
The filter cake was rinsed with MeOH (3 x 15 mL) and the solvent was removed under reduced 
pressure. The crude product was dissolved in a minimal amount of EtOH and concentrated to 
yield a mixture of 1-21b and EtOH (3 : 1) (0.159 g, 85%) as an orange powder: Mp > 225 °C 
(dec., EtOH); IR (ATR, EtOH) 3307, 1594, 1103, 982 cm-1; 1H NMR (CD3OD, 500 MHz) δ 7.89 
(s, 2 H), 7.85 (t, 2 H, J = 1.0 Hz), 4.56 (d, 4 H, J = 1.0 Hz); 13C NMR (CD3OD, 125 MHz) δ 
160.2, 144.1, 137.5, 137.4, 131.9, 57.1; HRMS (ESI+) m/z calcd for C12H11O4N2Se (M+H)+ 
326.9879, found 326.9868. ELSD purity = 98%. 
 
O BrEtO2C
 
1-23 
Ethyl 5-bromofuran-2-carboxylate (1-23).128 A solution of 5-bromofuran-2-carboxylic acid (1-
22) (2.00 g, 10.3 mmol) and H2SO4 (2 mL) in EtOH (50 mL) was stirred at reflux for 48 h under 
N2. After the first 36 h, Na2SO4 (1.00 g) was added to the solution. The volatiles were removed 
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under reduced pressure. The residue was poured into water (200 mL) and extracted with EtOAc 
(3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried (Na2SO4), and 
concentrated to yield 1-17 (2.11 g, 93%) as an orange liquid: 1H NMR (CDCl3, 400 MHz) δ 7.12 
(d, 1 H, J = 3.2 Hz), 6.45 (d, 1 H, J = 3.6 Hz), 4.36 (q, 2 H, J = 7.2 Hz), 1.37 (t, 3 H, J = 7.2 Hz).  
 
OEtO2C
 
1-24 
Ethyl 5-ethynylfuran-2-carboxylate (1-24). To a stirring solution of 1-23 (0.300 g, 1.37 mmol), 
CuI (0.006 g, 0.03 mmol), PdCl2(PPh3)2 (0.020 g, 0.028 mmol) in Et3N (3 mL) was added 
ethynyltrimethylsilane (0.40 mL, 2.8 mmol). The reaction solution was flushed with N2, sealed, 
and stirred at 50 °C in an oil bath for 24 h. The reaction mixture was filtered through Celite and 
rinsed with hexanes (50 mL). The filtrate was concentrated to yield a dark red liquid. The crude 
liquid was dissolved in EtOH (3 mL) and K2CO3 (0.170 g, 1.23 mmol) was added. The mixture 
was stirred at 50 °C for 1 h. The solvent was removed under reduced pressure and the residue 
was purified by chromatography on SiO2 (gradient: 0 – 4 % EtOAc/hexanes) to yield 1-24 (0.154 
g, 65%) as a yellow oil: IR (ATR) 3282, 2975, 1717, 1292 cm-1; 1H NMR (CDCl3, 300 MHz) δ 
7.13 (d, 1 H, J = 3.6 Hz), 6.70 (d, 1 H, J = 3.6 Hz), 4.37 (q, 2 H, J = 7.2 Hz) , 3.43 (s, 1 H), 1.38 
(t, 3 H, J = 7.2 Hz); 13C NMR (CDCl3, 100 MHz) δ 158.1, 145.2, 139.2, 118.3, 117.6, 83.6, 73.1, 
61.5, 14.4; HRMS (ESI+) m/z calcd for C9H9O3 (M++H) 165.0546, found 165.0546. 
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O NEtO2C
NN
O CO2Et
 
1-25 
Diethyl 5,5'-(1H-1,2,3-triazole-1,4-diyl)bis(furan-2-carboxylate) (1-25). Alkyne 1-24 (0.175 
g, 1.07 mmol), bromo-furan 1-23 (0.467 g, 2.13 mmol), sodium azide (0.278 g, 4.28 mmol), 
sodium ascorbate (0.042 g, 0.21 mmol), DMEDA (46 µL, 0.43 mmol), and CuI (0.042 g, 0.22 
mmol) were dissolved in deoxygenated EtOH/H2O (10 mL, 7:3). The reaction vial was flushed 
with Ar, sealed, and stirred at 75 °C for 4 d. The reaction solution was allowed to cool to rt and 
poured into ice-water (50 mL). To the beige aqueous solution was added NH4OH (10 mL, 28-
30% purity). The aqueous solution was extracted with EtOAc (3 x 50 mL). The combined 
organic layers were dried (Na2SO4) and concentrated. The residue was purified by 
chromatography on SiO2 (gradient: 0 – 50% EtOAc/hexanes) to yield 1-25 (0.228 g, 62%) as a 
light yellow solid: Mp 152.5 – 152.9 °C (CH2Cl2); IR (ATR) 3124, 1713, 1294, 1137 cm-1; 1H 
NMR (CDCl3, 300 MHz) δ 8.54 (s, 1 H), 7.32 (d, 1 H, J = 3.6 Hz), 7.28 (d, 1 H, J = 3.6 Hz), 
7.07 (d, 1 H, J = 3.6 Hz), 6.86 (d, 1 H, J = 3.6 Hz), 4.42 (q, 2 H, J = 7.2 Hz), 4.40 (q, 2 H, J = 7.2  
Hz), 1.42 (t, 3 H, J = 7.2 Hz), 1.41 (t, 3 H, J = 7.2 Hz); 13C NMR (CDCl3, 100 MHz) δ 158.7, 
158.0, 148.6, 145.6, 144.7, 142.0, 139.9, 119.9, 119.6, 118.4, 109.6, 100.4, 61.7, 61.3, 14.50, 
14.46; HRMS (ESI+) m/z calcd for C16H16N3O6 (M++H) 346.1034, found 346.1032.  
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O N
NN
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1-26 
((1H-1,2,3-Triazole-1,4-diyl)bis(furan-5,2-diyl))dimethanol (1-26). LiAlH4 in diethyl ether 
(0.6 mL, 1M) was added slowly to a stirring solution of 1-25 (0.120 g, 0.348 mmol) in THF (1.7 
mL, 0.2 M) at -10 °C (MeOH/ice). The solution was stirred for 1.5 h at the same temperature. 
Sequentially, water (25 µL), 15% NaOH solution (25 µL), and then water (80 µL) were added to 
the reaction mixture. The mixture was stirred for 1 hr. The reaction mixture was dried (Na2SO4), 
diluted with i-PrOH (5 mL), and filtered through Celite. The filter cake was washed with 
IPA:MeOH (1:1) and the filtrate was concentrated to yield 1-26 (0.075 g, 83%) as a dark yellow 
solid: Mp >80 °C (dec., MeOH); IR (ATR) 3359, 3233, 3107, 2932, 2841, 1629, 1450, 1014, 
798 cm-1; 1H NMR ((CD3)2SO, 300 MHz) δ 8.89 (s, 1 H), 6.84 (d, 1 H, J = 3.3 Hz), 6.80 (d, 1 H, 
J = 3.3 Hz), 6.55 (d, 1 H, J = 3.6 Hz), 6.45 (d, 1 H, J = 3.3 Hz), 4.47 (s, 2 H), 4.46 (s, 2 H); 13C 
NMR (CD3OD, 125 MHz) δ 156.7, 154.8, 146.0, 144.0, 141.4, 110.5, 110.3, 109.3, 101.7, 57.4, 
57.2; HRMS (ESI+) m/z calcd for C12H12N3O4 (M+H)+ 262.0822, found 262.0816; ELSD purity 
100%.  
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1-27, 1-28 
(tentative structural assignments) 
 
A solution of 1-1 in DMSO at a concentration of 15 mg/mL was allowed to sit benchtop for five 
weeks. Then, the crude mixture was analyzed by 1H, 13C, COSY, HSQC, and HMBC NMR and 
high-resolution LC/MS. Due to its symmetry, the geometry of the double bond in 1-27 could not 
be assigned. The compound may be E or Z.  
1,4-Bis(5-(hydroxymethyl)thiophen-2-yl)but-2-ene-1,4-dione (1-27): 1H NMR ((CD3)2SO, 
600 MHz) δ 7.76 (d, 2 H, J = 4.2 Hz), 7.25 (s, 2 H), 7.06 (d, 2 H, J = 4.2 Hz), 4.68 (s, 4 H) [-OH 
peaks not identified]; 13C NMR ((CD3)2SO, 150 MHz) δ 184.3, 158.1, 141.3, 134.8, 134.3, 
125.0, 58.7; HRMS (ESI+) m/z calcd for C14H13O4S2 (M+H)+ 309.0250, found 309.0247.  
(E)-3-(5-(Hydroxymethyl)thiophen-2-yl)-3-oxoprop-1-en-1-yl 5-(hydroxymethyl)thiophene-
2-carboxylate (1-28): 1H NMR ((CD3)2SO, 600 MHz) δ 8.32 (d, 1 H, J = 12 Hz), 8.03 (d, 1 H, J 
= 4.2 Hz), 7.93 (d, 1 H, J = 3.6 Hz), 7.23 (d, 1 H, J = 12 Hz), 7.15 (d, 1 H, J = 3.6 Hz), 7.10 (d, 1 
H, J = 4.2 Hz), 4.75 (s, 2 H), 4.74 (s, 2H) [-OH peaks not identified]; 13C NMR (characteristic 
peaks) ((CD3)2SO, 150 MHz) δ 181.5, 158.9, 157.8, 148.9, 143.0, 136.5, 134.0, 127.7, 125.0, 
124.5, 109.7, 58.7 (2 C); HRMS (ESI+) m/z calcd for C14H13O5S2 (M+H)+ 325.0199, found 
325.0196. 
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Plasma Stability Assay 
Balb C mouse plasma with K3 EDTA was purchased from Innovative Research™. Phosphate-
buffered saline (PBS) pH 7.4 (1x) was purchased from GIBCO. Procaine hydrochloride (positive 
control) and procainamide hydrochloride (negative control) were purchased from Acros and used 
as is. 
Plasma Preparation: 
The plasma was thawed to room temperature and placed in a centrifuge at 3000 rpm for 10 min 
to pellet any insoluble material. The supernatant was diluted in PBS pH 7.4 (1X) to prepare a 1:1 
solution (50% plasma v/v). The solution was warmed to 37 °C for 30 min while the stock 
compound solutions were prepared.   
Compound Stock Solution Preparation: 
Stock solutions of 1-1, 1-15b, 1-15f, procaine HCl, and procainamide HCl in DMSO were 
prepared at 400 µM.  
Testing Sample Preparation: 
A solution of plasma/PBS (195 µL) was dispensed into 1.5 mL Eppendorf tubes (N = 3 per 
compound). Then, 5 µL of compound stock solution was added for a final DMSO concentration 
of 2.5%. The solution was mixed 4x by aspirating and dispensing with a pipette. Immediately 
after mixing, 50 µL of the test mixture was quenched by aspirating and dispensing into a 1.5 mL 
Eppendorf tube containing 400 µL of ice cold solution of acetonitrile and caffeine (internal 
standard). This aliquot marks the “no incubation” time point. The remaining 150 µL of the test 
solution was sealed and incubated at 37 °C on a gentle shaker (300 rpm). The quenching step 
was repeated as described above after 1.5 h and 3 h of incubation. 
The quenched material was vortexed for 10 s, centrifuged at 3000 rpm for 10 minutes,  
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and filtered through 0.45 µM syringe filters into LC/MS vials. The samples were analyzed by 
high resolution LC/MS using mass guided peak search. The test compound peak was integrated 
and compared to the internal standard to determine the relative quantity of compound remaining.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88 
3.3 CHAPTER 2 EXPERIMENTAL PART 
S
NH
O
NH2  
2-2 
7-Amino-2-phenylthieno[3,2-c]pyridin-4(5H)-one (2-2).111d 
Route 1: 
A solution of 2-9 (0.280 g, 0.915 mmol) and conc. H2SO4 (7 mL) was heated to 80 °C, treated 
with conc. HNO3 (0.5 mL), and heated at 80 °C for 1 h. The reaction mixture was allowed to 
cool to rt, stirred for 5 h, neutralized with 5 N NaOH, washed with water, and extracted with 
EtOAc. The combined organic layers were dried (MgSO4), filtered, and concentrated to give a 
yellow solid that was purified by chromatography on SiO2 (0 – 100% EtOAc/hexanes) to obtain 
crude 7- nitro-2-phenylthieno[3,2-c]pyridin-4(5H)-one (0.142 g, ca. 44%) as a yellow solid. The 
crude solid (0.0272 g) was dissolved in EtOH (50 mL) and was reduced and debrominated using 
a 10% Pd/C cartridge in an H-cube instrument (pressure: 1 atm, temp. 50 °C, flow rate 1 
mL/min) for 1 h. The reaction mixture was evaporated under reduced pressure to obtain the 
crude product as a white powder which turned red upon standing at room temperature. The crude 
product was purified by SFC (MeOH, isocratic at 35% and 10 mL/min; retention time: 4.66 min) 
to obtain 3-2 (0.00370 g, 0.0153 mmol, 9% over 2 steps) as a pink solid. 
 
Route 2: 
A solution of HNO3 (0.100 g, 1.10 mmol, 69% grade) in glacial AcOH (1 mL) was added to a 
solution of 2-13 (0.075 g, 0.33 mmol) in AcOH (2 mL). The yellow reaction mixture was stirred 
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at rt for 15.5 h and turned dark orange. It was diluted with water (15 mL) and the yellow 
precipitate was filtered and washed with water (3 x 5 mL) to yield a yellow solid. A solution of 
the solid in EtOAc was washed with water (15 mL), sat. aq. NaHCO3 (2 x 15 mL), and brine (15 
mL), dried (Na2SO4), and concentrated to yield a yellow residue (ca. 0.070 g) that was treated 
with 10% Pd/C (0.047 g, 0.044 mmol, 17 mol%) in EtOH (10 mL). The reaction flask was 
flushed with N2 (3x) and then H2 was bubbled through the solution. The reaction mixture was 
stirred at rt under H2 (1 atm, balloon) for 5 h, filtered through basic Celite (EtOH), and 
concentrated to a dark residue that was purified by semi-prep SFC (MeOH, isocratic at 27% and 
7.5 mL/min; collection/retention time: 7.25-10.25 min) to yield 2-2 (15.3 mg, 19% over 2 steps) 
as a yellow-brown solid: 1H NMR ((CD3)2SO, 300 MHz) δ 10.85 (bs, 1 H), 7.83 (s, 1 H), 7.75 
(d, 2 H, J = 7.2 Hz), 7.46 (t, 2 H, J = 7.2 Hz), 7.38-7.33 (m, 1 H), 6.66 (s, 1 H), 4.46 (s, 2 H); 13C 
NMR ((CD3)2SO, 100 MHz) δ 156.5, 142.9, 141.0, 133.2, 131.1, 129.3, 128.2, 125.6, 124.3, 
120.7, 112.21; HRMS (ESI+) m/z calcd for C13H11ON2S (M+H)+ 243.0587, found 243.0586. 
 
S CHO  
2-5 
5-Phenylthiophene-2-carbaldehyde (2-5).111d,129 A mixture of phenyl boronic acid (0.770 g, 
6.32 mmol), Na2CO3 (1.21 g, 11.4 mmol), and Pd(PPh3)4 (0.300 g, 0.286 mmol) in a microwave 
vial was evacuated and refilled with Ar (3x), dissolved in deoxygenated 1,4-dioxane/H2O (2:1, 
17 mL), and treated with 5-bromothiophene-2-carboxaldehyde (2-4) (1.12 g, 5.69 mmol). The 
vial was sealed and heated in a microwave reactor at 90 °C for 2 h. The biphasic mixture was 
diluted with water (15 mL), and the precipitate was filtered and washed with water (100 mL). 
The residue was purified by chromatography on SiO2 (0 – 25% EtOAc/hexanes) to yield 2-5 
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(1.01 g, 95%) as a light pink solid: Mp 94.6-95.1 °C (CH2Cl2) (lit. 92-94 °C); IR (ATR) 3092, 
1637, 1439, 1228, 1062 cm-1; 1H NMR (CDCl3, 400 MHz) δ 9.89 (s, 1 H), 7.74 (d, 1 H, J = 3.6 
Hz), 7.68-7.65 (m, 2 H), 7.45-7.37 (m, 4 H); 13C NMR (CDCl3, 100 MHz) δ 182.9, 154.4, 142.6, 
137.5, 133.2, 129.6, 129.3, 126.5, 124.2; HRMS (ESI+) m/z calcd for C11H9OS (M+H)+ 
189.0369, found 189.0368. 
 
S CHO
Br
 
2-6 
4-Bromo-5-phenylthiophene-2-carbaldehyde (2-6).111d,130 Bromine (0.09 mL, 2 mmol) was 
added to a solution of 2-5 (0.300 g, 1.59 mmol) in CHCl3/AcOH (1:1, 4 mL). The reaction 
mixture was shielded from light, stirred for 20 h, and diluted with EtOAc (15 mL). The organic 
layer was washed with sat. aq. NaHCO3 (2 x 15 mL), aq. Na2S2O3 (2 x 15 mL), and brine (15 
mL), dried (Na2SO4), and concentrated to yield 2-6 (0.418 g, 98%) as yellow oil, which 
solidified upon standing to a light pink solid: Mp 81.7-82.5 °C (CH2Cl2) (lit. 83 °C); IR (ATR) 
3051, 1677, 1663, 1430, 1217, 1124 cm-1; 1H NMR (CDCl3, 400 MHz) δ 9.85 (s, 1 H), 7.72 (s, 1 
H), 7.70- 7.67 (m, 2 H), 7.49-7.45 (m, 3 H); 13C NMR (CDCl3, 100 MHz) δ 181.9, 148.2, 141.5, 
140.0, 131.9, 129.8, 129.1, 128.9, 108.9; HRMS (ESI+) m/z calcd for C11H8BrOS (M+H)+ 
266.9474, found 266.9473. 
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Br
CO2H  
2-7 
(E)-3-(4-Bromo-5-phenylthiophen-2-yl)acrylic acid (2-7).111d Malonic acid (0.094 g, 0.90 
mmol) was added to a solution of 2-6 (0.200 g, 0.749 mmol) in pyridine (5 mL) and piperidine 
(0.25 mL). The reaction mixture was stirred at reflux for 5.5 h, allowed to cool to rt, poured over 
ice and dropwise treated with 12 N HCl (15 mL). The aqueous layer was extracted with EtOAc 
(100 mL) and the combined organic layers were washed with 1 N HCl (100 mL) and brine (100 
mL), dried (Na2SO4), and concentrated to give 2-7 (0.203 g, 88%) as a yellow solid: Mp 169.1-
171.9 °C (EtOAc); IR (ATR) 3300-2200 (br), 1676, 1614, 1413, 1273, 1195 cm-1; 1H NMR 
((CD3)2SO, 400 MHz) δ 12.6 (bs, 1 H), 7.70 (d, 1 H, J = 16.0 Hz), 7.66-7.64 (m, 3 H), 7.55-7.45 
(m, 3 H), 6.28 (d, 1 H, J = 16.0 Hz); 13C NMR ((CD3)2SO, 100 MHz) δ 166.8, 139.6, 138.2, 
135.1, 134.7, 131.6, 129.0, 128.9, 128.5, 119.1, 107.9; HRMS (ESI+) m/z calcd for C13H10BrO2S 
(M+H)+ 308.9579, found 308.9578. 
 
S
Br
CON3  
2-8 
(E)-3-(4-Bromo-5-phenylthiophen-2-yl)acryloyl azide (2-8).111d A stirred suspension of 2-7 
(0.650 g, 2.10 mmol) and DMF (0.1 mL) in toluene (10 mL) was treated dropwise with thionyl 
chloride (0.183 mL, 2.52 mmol) at room temperature, heated to reflux for 2.5 h, cooled to room 
temperature, and concentrated under reduced pressure to obtain crude acid chloride (0.660 g) as a 
brown oil that was used without further purification. A stirred suspension of NaN3 (0.261 g, 4.03 
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mmol) in a mixture of toluene (2.5 mL) and water (2.5 mL) was treated dropwise with a solution 
of the crude oil (0.660 g) in toluene (2.5 mL) at 0 °C. The suspension was stirred for 1.5 h at 
room temperature. The toluene layer was then isolated and concentrated in vacuo, dissolved in 
EtOAc (5 mL), dried (MgSO4), filtered, and concentrated under reduced pressure. The residue 
was purified by chromatography on SiO2 (0 – 10% EtOAc/hexanes) to give 2-8 (0.310 g, 44% 
over 2 steps) as a yellow solid: IR (ATR) 2135, 1677, 1610, 1431, 1129 cm-1; 1H NMR (THF-d8, 
500 MHz) δ 7.81 (d, 1 H, J = 15.5 Hz), 7.70-7.67 (m, 2 H), 7.54 (s, 1 H), 7.47-7.40 (m, 3 H), 
6.34 (d, 1 H, J = 15.5 Hz); 13C NMR (THF-d8, 75 MHz) δ 171.3, 142.7, 138.7, 137.9, 136.9, 
132.9, 129.8, 129.4 (2 C), 119.3, 109.2; EIMS m/z 335 (50), 333 (35), 307 (95), 293 (55), 198 
(95), 171 (100); HRMS (EI) m/z calcd for C13H8BrN3OS 332.9571, found 332.9571. 
 
S
Br
NH
O
 
2-9 
3-Bromo-2-phenylthieno[3,2-c]pyridin-4(5H)-one (2-9).111d A solution of azide 2-8 (0.101 g, 
0.302 mmol) in diphenyl ether (2.5 mL) was heated in a microwave vial to 250 °C for 30 min. 
The dark brown reaction mixture was purified by chromatography on SiO2 (20 – 70% 
EtOAc/hexanes) to give 2-9 (0.0481 g, 0.157 mmol, 52%) as a buff colored solid: Mp 239-240 
°C; IR (ATR) 3313, 1684, 1638, 1602, 1591, 1494, 1440, 1192 cm-1; 1H NMR (CDCl3, 300 
MHz) δ 11.96 (bs, 1 H), 7.68-7.66 (m, 2 H), 7.50-7.46 (m, 3 H), 7.33 (d, 1 H, J = 6.6 Hz), 6.74 
(d, 1 H, J = 6.6 Hz); 13C NMR (CDCl3, 125 MHz) δ 160.5, 148.9, 137.0, 132.5, 130.0, 129.6, 
129.1, 128.8, 127.1, 105.7, 102.2; HRMS (TOF MS ES+) m/z calcd for C13H9BrNOS (M+H)+ 
305.9588, found 305.9583. 
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2-10 
(E/Z)-2-(2-Iodovinyl)-5-phenylthiophene (2-10). NaHMDS (0.154 g, 0.787 mmol) in 
anhydrous THF (2 mL) was added dropwise to a suspension of 2-15 (0.446, 0.841 mmol) in 
anhydrous THF (5 mL) at 0 °C under N2. The resulting mixture was stirred at rt for 10 min and 
then cooled to -78 °C. Aldehyde 2-5 (0.099 g, 0.53 mmol) in anhydrous THF (3 mL) was added 
dropwise and the mixture was stirred at -78 °C under N2 for 40 min. The reaction was quenched 
with the addition of sat. aq. NH4Cl (30 mL) and extracted with ether (30 mL). The organic layer 
was washed with water (30 mL) and brine (30 mL), dried (Na2SO4), and concentrated to an 
orange oil. The oil was purified by chromatography on SiO2 (hexanes then 5% EtOAc/hexanes) 
to yield 2-10 (0.085 g, 52%) as a 1:1 E/Z mixture of a colorless solid: 1H NMR (CDCl3, 300 
MHz) for the isomeric mixture δ 7.68-7.56 (m, 5 H), 7.46 (d, 1 H, J = 14.7 Hz), 7.40-7.29 (m, 8 
H), 7.18 (d, 1 H, J = 3.6 Hz), 6.91 (d, 1 H, J = 3.9 Hz), 6.64 (d, 1 H, J = 15.0 Hz), 6.44 (d, 1 H, J 
= 8.4 Hz).  
 
P I
I  
2-15 
(Iodomethyl)triphenylphosphonium iodide (2-15).115 Diiodomethane (1.25 mL, 15.5 mmol) 
was added to a solution of triphenylphosphine (2-14) (3.00 g, 11.4 mmol) in toluene (10 mL) in a 
vial under Ar. The vial was sealed and the resulting yellow solution was shielded from light with 
aluminum foil, stirred at reflux for 24 h, and allowed to cool to rt. The residue was filtered, 
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washed with cold toluene (100 mL), and dried to yield 2-15 (5.38 g, 89%) as a colorless solid: 1H 
NMR ((CD3)2SO, 400 MHz) δ 7.94-7.74 (m, 15 H), 5.07 (d, 2 H, JHP = 8.8 Hz). 
 
S
NH
O
 
2-17 
6,7-Dihydrothieno[3,2-c]pyridin-4(5H)-one (2-17).111d,131 Thiophene-2-ethylamine (2-16) (1.0 
mL, 8.4 mmol) was added dropwise to a three neck flask (one gas inlet, two rubber septa) 
containing a solution of triphosgene (1.25 g, 4.21 mmol) in anhydrous CH2Cl2 (12 mL) at 0 °C 
under Ar, followed by the addition of sat. aq. NaHCO3 (12 mL) over 5 min. The resulting 
biphasic mixture was stirred at 0 °C under Ar for 5 h. The organic layer was dried (Na2SO4), 
passed through a short SiO2 column (CH2Cl2), and concentrated to yield crude 2-(2-
isocyanatoethyl)thiophene as an oil: IR (ATR) 2263 (NCO) cm-1. A solution of this oil in 
anhydrous CH2Cl2 (25 mL) was added to a mixture of anhydrous FeCl3 (1.36 g, 8.37 mmol) in 
anhydrous CH2Cl2 (100 mL) under N2. The flask was equipped with a condenser and the reaction 
mixture was stirred at 50 °C for 40 min, poured into sat. aq. NH4Cl (25 mL), extracted with 
CH2Cl2 (2 x 25 mL), and dried (Na2SO4). The solution was passed through a short basic Al2O3 
column (10% MeOH/CH2Cl2) and concentrated to yield 2-17 (0.976 g, >90% pure based on 
NMR analysis, 71% over two steps) as a viscous dark oil with minor solvent impurities: 1H 
NMR (CDCl3, 400 MHz) δ 7.41 (d, 1 H, J = 5.2 Hz), 7.10 (d, 1 H, J = 5.2 Hz), 6.46 (bs, 1 H), 
3.64 (dt, 2 H, J = 6.8, 2.8 Hz), 3.05 (t, 2 H, J = 6.8 Hz); 13C NMR (CDCl3, 100 MHz) δ 164.2, 
146.3, 132.2, 126.0, 123.2, 41.3, 24.5. 
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2-18 
2-Bromo-6,7-dihydrothieno[3,2-c]pyridin-4(5H)-one (2-18).111d,132 After addition of Br2 (0.11 
mL, 2.1 mmol) to a solution of 2-17 (0.300 g, 1.96 mmol) in AcOH (6 mL), the red reaction 
mixture was shielded from light and stirred at rt for 12 h, neutralized (Na2CO3), and diluted with 
EtOAc (30 mL). The organic layer was washed with sat. aq. NaHCO3 (30 mL), aq. Na2S2O3 (30 
mL), and brine (30 mL), dried (Na2SO4), and concentrated to yield 2-18 (0.340 g, 75%) as a 
brown solid: Mp >100 °C (dec., CH2Cl2); IR (ATR) 3195, 3059, 2930, 1664, 1478, 1430, 1286 
cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.36 (s, 1 H), 6.24 (bs, 1 H), 3.63 (dt, 2 H, J = 6.8, 2.8 Hz), 
2.97 (t, 2 H, J = 6.8 Hz); 13C NMR (CDCl3, 100 MHz) δ 162.6, 147.4, 132.9, 128.5, 110.4, 41.2, 
24.5; HRMS (ESI+) m/z calcd for C7H7BrNOS (M+H)+ 231.9426, found 231.9425. 
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2-13a, 2-13 
2-Phenylthieno[3,2-c]pyridin-4(5H)-one (2-13).111d,133 A mixture of bromide 2-18 (0.200 g, 
0.862 mmol), phenyl boronic acid (0.127 g, 1.04 mmol), Pd(PPh3)4 (0.045 g, 0.043 mmol), and 
Na2CO3 (0.211 g, 2.00 mmol) in a microwave vial was flushed with Ar (3x), diluted with 
deoxygenated 1,4-dioxane/H2O (2:1, 10 mL) and sealed. The reaction mixture was heated in an 
oil bath to 90 °C for 24 h, concentrated, and purified by chromatography on SiO2 (50 – 100% 
EtOAc/hexanes) to yield 2-phenyl-6,7-dihydrothieno[3,2-c]pyridin-4(5H)-one (2-13a) as a crude 
solid (0.178 g) with minor aromatic impurities. The solid was typically used in the next step 
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without further purification. Analytically pure compound was acquired by washing with ether in 
a sonication bath: Mp 173.3-175.1 °C (CH2Cl2); IR (ATR) 3211 (br.), 3062, 2947, 2901, 1657, 
1483, 1430, 754 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.63 (s, 1 H), 7.59-7.56 (m, 2H), 7.39 7.36 
(m, 2 H), 7.31-7.27 (m, 1 H), 6.75 (bs, 1 H), 3.67 (dt, 2 H, J = 6.8, 2.8 Hz), 3.06 (t, 2 H, J = 6.8 
Hz); 13C NMR (CDCl3, 100 MHz) δ 164.1, 145.6, 142.3, 133.7, 133.1, 129.1, 128.0, 125.8, 
121.3, 41.2, 24.5; HRMS (ESI+) m/z calcd for C13H12NOS (M+H)+ 230.0634, found 230.0632. 
After addition of DDQ (0.218 g, 0.932 mmol) under an atmosphere of Ar to a solution of 
crude 2-13a (0.178 g) in 1,4-dioxane (15 mL), the dark reaction mixture was stirred at 101 °C in 
a sealed vial under an Ar atmosphere for 1.5 d. Additional DDQ (0.218 g, 0.932 mmol) was 
added and heating was continued for another 24 h. The dark solution was concentrated to a crude 
brown solid that was purified by chromatography on SiO2 (0-100% EtOAc/hexanes) to yield a 
crude light yellow solid with red and orange impurities. The crude solid was suspended in a 
small amount of EtOAc (<5 mL), filtered, and dried under vacuum to yield 2-13 (0.094 g, 48% 
over 2 steps) as light yellow solid: Mp >245 °C (dec., EtOAc); IR (ATR) 2828 (br), 1638, 1597, 
1500, 1215, 749, 686 cm-1; 1H NMR ((CD3)2SO, 400 MHz) δ 11.47 (bs, 1 H), 7.86 (s, 1 H), 7.75 
(d, 2 H, J = 7.2 Hz), 7.45 (t, 2 H, J = 7.2 Hz), 7.38-7.34 (m, 1 H), 7.27 (d, 1 H, J = 7.2 Hz), 6.85 
(d, 1 H, J = 7.2 Hz); 13C NMR ((CD3)2SO, 100 MHz) δ 158.6, 147.6, 141.2, 133.0, 131.6, 130.0, 
129.3, 128.3, 125.7, 119.9, 100.9; HRMS (ESI+) m/z calcd for C13H10NOS (M+H)+ 228.0478, 
found 228.0474. 
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2-21 
Methyl 2-amino-5-phenylthiophene-3-carboxylate (2-21).111d,134 After addition of Et3N (1.2 
mL, 8.5 mmol) to a stirred mixture of phenylacetaldehyde (2-20) (1.0 mL, 8.4 mmol), methyl 
cyanoacetate (2-24) (0.80 mL, 8.8 mmol) and elemental sulfur (0.269 g, 8.40 mmol) in DMF (8.4 
mL, 1 M), the reaction mixture was stirred at rt for 21 h and then diluted with water (10 mL). 
The yellow precipitate was filtered, washed with water (40 mL) and then hexanes (50 mL), and 
dried under vacuum to yield 2-21 (1.77 g, 90%) as a light yellow solid: Mp 183.8-185.1 °C (lit. 
194.5 °C); IR (ATR) 3459, 3348, 2943, 1664, 1569, 1543, 1484, 1230 cm-1; 1H NMR 
((CD3)2SO, 400 MHz) δ 7.50 (bs, 2 H), 7.46-7.43 (m, 2 H), 7.35-7.31 (m, 2 H), 7.24 (s, 1 H), 
7.20-7.16 (m, 1 H), 3.73 (s, 3 H); 13C NMR ((CD3)2SO, 100 MHz) δ 164.6, 163.5, 133.7, 128.9, 
126.2, 124.0, 122.3, 121.0, 104.7, 50.7; HRMS (ESI+) m/z calcd for C12H12NO2S (M+H) 
234.0583, found 234.0576. 
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2-22 
6-Phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (2-22).111d,135 Chlorosulfonyl isocyanate 
(0.15 mL, 1.7 mmol) was added slowly at -78 °C to a solution of 2-21 (0.200 g, 0.857 mmol) in 
CH2Cl2 (1.5 mL). The reaction mixture was allowed to warm to rt and stirred for 40 min. The 
slurry was concentrated and then diluted with wet 1,4-dioxane (4 mL), stirred at rt for 15 min 
and then at 85 °C for 30 min and treated with conc. NaOH (1 mL) so that the final concentration 
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of the base was 1 M. Heating at 85 °C was continued for 30 min and then the reaction mixture 
was allowed to cool to rt, diluted with water (5 mL), and acidified with conc. HCl with stirring 
until precipitation stopped. The precipitate was filtered, washed with water (20 mL), and dried 
under vacuum to yield 2-22 (0.120 g, 57%) as a colorless solid: Mp >300 °C (dec.); IR (ATR) 
3159, 3044, 2806, 1707, 1653, 1555, 1256 cm-1; 1H NMR ((CD3)2SO, 400 MHz) δ 12.03 (s, 1 
H), 11.21 (s, 1 H), 7.65-7.63 (m, 2 H), 7.55 (s, 1 H), 7.42-7.38 (m, 2 H), 7.32-7.29 (m, 1 H); 13C 
NMR ((CD3)2SO, 100 MHz) δ 159.1, 151.4, 150.5, 133.3, 132.6, 129.2, 127.8, 125.1, 117.6, 
116.2; HRMS (ESI+) m/z calcd for C12H9N2O2S (M+H)+ 245.0379, found 245.0378.  
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2-26 
Methyl 2-amino-4,5-diphenylthiophene-3-carboxylate (2-26). Titanium tetrachloride (0.44 
mL, 4.0 mmol) was added to a stirring solution of deoxybenzoin (2-25) (0.400 g, 1.98 mmol) and 
2-24 (0.20 mL, 2.2 mmol) in CH2Cl2 (20 mL) at 0 °C under N2. After stirring for 5 min, pyridine 
(0.34 mL, 4.1 mmol) was added dropwise at 0 °C under N2. The mixture was stirred for 30 min 
at 0 °C and then for 22 h at rt. The solvent was removed under reduced pressure and the residue 
was diluted with EtOAc (15 mL). The organic layer was washed with 1N HCl (2 x 15 mL), water 
(15 mL), and brine (15 mL), dried (Na2SO4), and concentrated to a brown oil. The crude oil was 
dissolved in MeOH (10 mL) with sulfur (0.066 g, 2.1 mmol), morpholine (0.20 mL, 2.3 mmol), 
and acetic acid (0.04 mL, 0.7 mmol). The mixture was stirred at reflux for 2 d. The solution was 
diluted with water (10 mL) to induce precipitation. The precipitate was filtered, washed with 
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water (20 mL) and hexanes (20 mL), and dried to yield 2-26 (0.531 g, 87%) as a brown solid: 
Mp > 118 °C (dec.); IR (ATR) 3409, 3307, 1642, 1594, 1439, 1269, 1236, 692 cm-1; 1H NMR 
((CD3)2SO, 400 MHz) δ 7.54 (bs, 2 H), 7.27-7.25 (m, 3 H), 7.14-7.06 (m, 5 H), 6.95-6.93 (m, 2 
H), 3.37 (s, 3 H); 13C NMR ((CD3)2SO, 100 MHz) δ 164.9, 163.4, 137.5, 135.9, 133.8, 129.8, 
128.2, 127.5, 126.7, 126.3, 118.8, 105.2, 50.2; HRMS (ESI+) m/z calcd for C18H16NO2S (M+H)+ 
310.0896, found 310.0898. 
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2-28 (tentative structural assignment) 
Methyl 2-(3-benzoylthioureido)-5-phenylthiophene-3-carboxylate (2-28).111d A solution of 
benzoyl chloride (0.50 mL, 4.3 mmol) and anhydrous ammonium thiocyanate (0.489 g, 6.43 
mmol) in anhydrous CH3CN (10 mL) was stirred at reflux for 30 min under N2 and then treated 
with a suspension of 2-21 (0.500 g, 2.14 mmol) in anhydrous CH3CN (5 mL). The reaction 
mixture was stirred for 6 h at reflux, cooled, and the precipitate was filtered, washed with water 
(75 mL), and dried under vacuum to yield 2-28 (0.583 g, 69%) as a fine bright yellow powder: 
Mp 229.6-231.2 °C (CH3CN); IR (ATR) 3275, 2943, 1694, 1670, 1508, 1221 cm-1; 1H NMR 
(CDCl3, 400 MHz) δ 14.78 (bs, 1 H), 9.17 (bs, 1 H), 7.98-7.96 (m, 2 H), 7.67-7.61 (m, 3 H), 
7.57-7.52 (m, 3 H), 7.41-7.37 (m, 2 H), 7.32-7.27 (m, 1 H), 4.02 (s, 3 H); 13C NMR (CDCl3, 100 
MHz) δ 174.0, 165.5, 164.9, 147.7, 134.8, 133.9, 133.7, 131.5, 129.3, 129.1, 127.9 (2 C), 125.9, 
100 
120.4, 118.3, 52.4; HRMS (ESI+) m/z calcd for C20H17N2O3S2 (M+H)+ 397.0675, found 
397.0673. 
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2-29 (tentative structural assignment) 
Methyl 2-(3-benzoylthioureido)thiophene-3-carboxylate (2-29).111d A mixture of benzoyl 
chloride (0.59 mL, 5.1 mmol) and anhydrous ammonium thiocyanate (0.581 g, 7.63 mmol) in 
anhydrous CH3CN (10 mL) was stirred at reflux for 30 min under N2, treated with a suspension 
of 2-27 (0.400 g, 2.54 mmol) in anhydrous CH3CN (5 mL), and stirred for 6 h at reflux and then 
cooled to 0 °C. The precipitate was filtered, washed with cold CH3CN (50 mL) and then water 
(75 mL), and dried under vacuum to yield 2-29 (0.543 g, 67%) as a yellow solid: Mp 179.7-
181.6 °C (EtOH); IR (ATR) 3422, 2934, 1683, 1543, 1148 cm-1; 1H NMR (CDCl3, 400 MHz) δ 
14.77 (bs, 1 H), 9.16 (bs, 1 H), 7.97-7.95 (m, 2 H), 7.66-7.62 (m, 1 H), 7.55-7.51 (m, 2 H), 7.37 
(d, 1 H, J = 6.0 Hz), 6.85 (dd, 1 H, J = 5.6, 0.4 Hz), 3.99 (s, 3 H); 13C NMR (CDCl3, 100 MHz) δ 
174.4, 165.5, 165.0, 148.7, 133.9, 131.6, 129.3, 127.9, 125.1, 117.5, 117.4, 52.3; HRMS (ESI+) 
m/z calcd for C14H13N2O3S2 (M+H)+ 321.0362, found 321.0360. 
 
 
101 
S N
H
NH
O
S
 
2-30 
6-Phenyl-2-thioxo-2,3-dihydrothieno[2,3-d]pyrimidin-4(1H)-one (2-30).111d,136 A suspension 
of 2-28 (0.100 g, 0.252 mmol) and KOH (0.100 g, 1.78 mmol) in EtOH (5 mL) was stirred at 
reflux for 14 h, cooled to rt, and acidified with aq. HCl. The colorless precipitate was filtered and 
washed with water (20 mL). The solid was then precipitated from EtOH, filtered and dried under 
vacuum to yield 2-30 (0.032 g, 49%) as an off-white solid: Mp >230 °C (dec., EtOH) (lit. >305 
°C, dec.); IR (ATR) 3059, 2932, 1653, 1543, 1199, 1126, 744 cm-1; 1H NMR ((CD3)2SO, 400 
MHz) δ 13.54 (bs, 1 H), 12.51 (bs, 1 H), 7.69 (d, 2 H, J = 7.6 Hz), 7.65 (s, 1 H), 7.43 (t, 2 H, J = 
7.6 Hz), 7.36-7.33 (m, 1 H); 13C NMR ((CD3)2SO, 100 MHz) δ 173.4, 156.5, 150.8, 135.9, 
132.3, 129.3, 128.3, 125.4, 119.8, 117.5; HRMS (ESI+) m/z calcd for C12H9N2OS2 (M+H)+ 
261.0151, found 261.0148. 
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2-31 
2-Thioxo-2,3-dihydrothieno[2,3-d]pyrimidin-4(1H)-one (2-31).111d,137 A suspension of 2-29 
(0.350 g, 1.09 mmol) and KOH (0.350 g, 6.24 mmol) in EtOH (15 mL) was stirred at reflux for 
19 h, cooled to rt and concentrated under reduced pressure. The residue was diluted with 1 N 
HCl (25 mL). The precipitate was filtered and washed with water (50 mL) to yield a brown solid. 
The solid was stirred in hot EtOH, cooled, filtered and dried under vacuum to yield 2-31 (0.115 
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g, 57%) as a fine yellow powder: Mp >280 °C (dec., EtOH) (lit. 305-307 °C, EtOH); IR (ATR) 
3059, 2898, 1629, 1553, 1523, 1450, 1187, 1128, 701 cm-1; 1H NMR ((CD3)2SO, 400 MHz) δ 
13.44 (bs, 1 H), 12.44 (bs, 1 H), 7.27 (d, 1 H, J = 5.6 Hz), 7.20 (d, 1 H, J = 5.6 Hz); 13C NMR 
((CD3)2SO, 100 MHz) δ 173.5, 156.7, 151.7, 121.8, 119.8, 118.7; HRMS (ESI+) m/z calcd for 
C6H5N2OS2 (M+H)+ 184.9838, found 184.9838. 
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2-32 
7-Imino-2-phenylthieno[3,2-c]pyridine-4,6(5H,7H)-dione (2-32).111d A solution of 2-2 (32.51 
mg, 0.1342 mmol) in MeOH (30 mL) in a 50 mL Pyrex® round bottom flask was placed 15 cm 
away from a 23 W compact fluorescent lamp and stirred at 23-24 °C until the starting material 
was consumed (2.5 days), as determined by high resolution LC/MS. Brown product 2-32 started 
to precipitate after 1 day. The mixture was concentrated under reduced pressure to remove about 
half of the solvent and the brown precipitate was filtered, washed with MeOH (5 mL) and dried 
under vacuum to yield a brown solid (14.86 mg). The filtrate was concentrated under reduced 
pressure to remove all of the solvent. The brown residue was washed with MeOH (5 mL) and 
dried under vacuum to yield a brown solid (11.72 mg). The solids were combined to yield 2-32 
(26.58 mg, 77%) as an amorphous brown solid. Both precipitates had the same purity based on 
1H NMR analysis. Yellow-green crystals were obtained from the slow evaporation of a solution 
of 2-32 in MeCN: Mp >260 °C (dec., MeOH); IR (ATR) 3239, 3095, 2823, 1695, 1598, 1453 
cm-1; 1H NMR ((CD3)2SO, 400 MHz) δ 11.87 (bs, 1H), 11.59 (s, 1 H), 7.98 (s, 1 H), 7.87 (d, 2 H, 
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J = 6.8 Hz), 7.52-7.43 (m, 3 H); 13C NMR ((CD3)2SO, 100 MHz) δ 160.1, 157.9, 153.4, 149.3, 
141.9, 136.8 132.0, 129.6, 129.5, 126.2, 122.1; HRMS (ESI+) m/z calcd for C13H9O2N2S 
(M+H)+ 257.0379, found 257.0378. The X-ray structure of 2-32 was deposited with the 
Cambridge Crystallographic Data Centre (CCDC 1476250). 
 
Reactions Conducted in the Lilly Automated Synthesis Lab 
General Procedure for Suzuki-Miyaura Cross-Coupling and Aromatization 
A mixture of halide 2-18 (1 mmol), aryl boronic acid (1.5 equiv.), and Na2CO3 (2.3 equiv.) in 
dioxane (7.8 mL) and water (2.6 mL) was deoxygenated by a passing through it a stream of N2 
for 15 min. Then, Pd(PPh3)4 (5 mol%) was added and the resulting mixture was stirred at 90 °C 
for 24 h, allowed to cool, passed through diatomaceous earth rinsing with EtOAc, and 
concentrated to a yield crude product 2-38. 
A mixture of crude 2-38 and DDQ (3.5 equiv.) in dioxane (12 mL) was stirred at 90 °C 
for 24 h, passed through a Celite cartridge rinsing with EtOAc, and concentrated to yield crude 
reaction product 2-40. The product was purified by mass-guided HPLC in the Automated 
Purification Lab (APL).  
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2-40b 
2-(3,5-Dimethylphenyl)thieno[3,2-c]pyridin-4(5H)-one (2-40b). Isolated as a brown solid (116 
mg, 45%): 1H NMR ((CD3)2SO, 400 MHz) δ 11.45 (bs, 1H), 7.81 (s, 1 H), 7.37 (s, 2 H), 7.26 (t, 
1 H, J = 6.8 Hz), 7.01 (s, 1 H), 6.84 (d, 1 H, J = 6.8 Hz), 2.33 (s, 6 H). 
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2-40c 
2-(4-Fluorophenyl)thieno[3,2-c]pyridin-4(5H)-one (2-40c). Isolated as a brown solid (64.8 mg, 
26%): 1H NMR ((CD3)2SO, 400 MHz) δ 11.47 (bs, 1H), 7.84 (s, 1 H), 7.83-7.79 (m, 2 H), 7.32-
7.26 (m, 3 H), 6.86 (d, 1 H, J = 6.8 Hz). 
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2-40d 
2-(4-(Trifluoromethyl)phenyl)thieno[3,2-c]pyridin-4(5H)-one (2-40d). Isolated as a brown 
solid (108 mg, 36%): 1H NMR ((CD3)2SO, 400 MHz) δ 11.54 (bs, 1H), 8.05 (s, 1 H), 7.99 (d, 2 
H, J = 8.0 Hz), 7.80 (d, 2 H, J = 8.0 Hz), 7.32 (t, 1 H, J = 6.4 Hz), 6.90 (d, 1 H, J = 7.2 Hz).  
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2-41a 
7-Bromo-2-phenylthieno[3,2-c]pyridin-4(5H)-one (2-41a).133 A solution of NBS in DMF (1.3 
equiv., 0.15 M) was added slowly over 10 min to a mixture of 2-13 (0.442 mmol) in DMF (1 
mL). The resulting mixture was stirred at 25 C for 12 h, passed through Celite rinsing with 
EtOAc, concentrated, and purified by mass-guided HPLC in APL to yield 2-41a (99.9 mg, 74%, 
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78% BRSM) as an off-white solid: 1H NMR ((CD3)2SO, 400 MHz) δ 11.81 (bs, 1H), 8.01 (s, 1 
H), 7.83-7.80 (m, 2 H), 7.60 (s, 1 H), 7.50-7.46 (m, 2 H), 7.42-7.36 (m, 1 H). 
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2-42a 
4-(Benzyloxy)-7-bromo-2-phenylthieno[3,2-c]pyridine (2-42a). A mixture of 2-41a (0.25 
mmol), BnBr (1.2 equiv.), and K2CO3 (1 equiv.) in dioxane (4 mL) was stirred at 70 °C for 16 h, 
passed through Celite rinsing with EtOAc, concentrated, and purified by mass-guided HPLC in 
APL to yield 2-42a (49.0 mg, 49%) as a light tan solid: 1H NMR ((CD3)2SO, 400 MHz) δ 8.13 
(s, 1 H), 8.03 (s, 1 H), 7.82-7.80 (m, 2 H), 7.49-7.46 (m,  2 H), 7.42-7.28 (m, 6 H), 5.22 (s, 2 H). 
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39e 
5-Ethyl-2-phenyl-6,7-dihydrothieno[3,2-c]pyridin-4(5H)-one (2-39e). Iodoethane (4.1 mmol) 
was added to a mixture of 2-13a (1.92 mmol) and a solution of KOt-Bu in THF (3.1 mmol, 1 M) 
at 25 °C. The resulting mixture was stirred at 55 °C for 20 h, passed through Celite rinsing with 
EtOAc, concentrated, and purified by mass-guided HPLC in APL to yield 2-39e (182 mg, 37%, 
53% BRSM) as an off-white solid: 1H NMR ((CD3)2SO, 400 MHz) δ 7.67-7.65 (m, 2 H), 7.60 (s, 
1 H), 7.45-7.41 (m, 2 H), 7.35-7.31 (m, 1 H), 3.65 (t, 2 H, J = 6.8 Hz), 3.47 (q, 2 H, J = 7.2 Hz), 
3.09 (t, 2 H, J = 6.8 Hz), 1.10 (t, 3 H, J = 7.2 Hz).   
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2-40e 
5-Ethyl-2-phenylthieno[3,2-c]pyridin-4(5H)-one (2-40e). A mixture of 2-39e (0.706 mmol) 
and DDQ (3.5 equiv.) in dioxane (11 mL) was stirred at 90 °C for 20 h, passed through Celite 
rinsing with EtOAc, concentrated, and purified by mass-guided HPLC in APL to yield 2-40e 
(160 mg, 89%) as  a tan solid: 1H NMR ((CD3)2SO, 400 MHz) δ 7.88 (s, 1 H), 7.77-7.75 (m, 2 
H), 7.61 (d, 1 H, J = 7.2 Hz), 7.48-7.44 (m, 2 H), 7.39-7.35 (m, 1 H), 6.93 (d, 1 H, J = 7.2 Hz), 
4.02 (q, 2 H, J = 7.2 Hz), 1.26 (t, 3 H, J = 7.2 Hz); 13C NMR ((CD3)2SO, 100 MHz) δ 158.0, 
146.8, 142.2, 134.1, 133.4, 131.6, 129.7, 128.8, 126.2, 120.7, 101.8, 43.7, 15.2. 
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2-41e 
7-Bromo-5-ethyl-2-phenylthieno[3,2-c]pyridin-4(5H)-one (2-41e). A solution of NBS in DMF 
(1.4 equiv., 0.2 M) was added over 10 min to a mixture of 2-40e (0.588 mmol) in DMF (0.5 mL) 
at 25 °C. The resulting mixture was stirred at 35 °C for 12 h, passed through Celite rinsing with 
EtOAc, concentrated, and purified by mass-guided HPLC in APL to yield 2-41e (97.9 mg, 50%, 
56% BRSM) as a brown solid: 1H NMR ((CD3)2SO, 400 MHz) δ 8.03 (s, 1 H), 8.02 (s, 1 H), 
7.83-7.81 (m, 2 H), 7.50-7.46 (m, 2 H), 7.42-7.83 (m, 1 H), 4.03 (q, 2 H, J = 7.2 Hz), 1.27 (t, 3 
H, J = 7.2 Hz). 
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SUPPLEMENTARY FIGURES AND SCHEMES 
 
 
Figure 18. A498 cell line xenograft studies in mice with compound 1-1. Drug treatment was 
administered by intravenous injections every 4 days for a total of three injections.45 
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Figure 19. Mean mouse weight response to NSC 652287 (1-1) in A498 xenograft study.45 
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Figure 20. NCI-60 cell panel displaying mean log10 GI50 for compound 1-15b.45 
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Figure 21. NCI-60 cell panel displaying mean log10 GI50 for compound 1-15c.45 
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Figure 22. NCI-60 cell panel displaying mean log10 GI50 for compound 1-15f.45 
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Figure 23. NCI-60 cell panel displaying mean log10 GI50 for the broadly cytotoxic triad 1-1.45 
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Figure 24. Crystal Structure of 2-32.138 
 
Table 10. Sample and crystal data for 2-32. 
Identification code salamoun 
Chemical formula C13H8N2O2S 
Formula weight 256.27 g/mol 
Temperature 230(2) K 
Wavelength 1.54178 Å 
Crystal size 0.005 x 0.080 x 0.160 mm 
Crystal habit clear yellow plate 
Crystal system triclinic 
Space group P -1 
Unit cell dimensions a = 6.4286(3) Å α = 89.263(2)° 
 b = 7.4520(3) Å β = 78.416(2)° 
 c = 11.7070(5) Å γ = 84.742(2)° 
Volume 547.09(4) Å3  
Z 2 
Density (calculated) 1.556 g/cm3 
Absorption coefficient 2.595 mm-1 
F(000) 264 
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Table 11. Data collection and structure refinement for 2-32. 
 
Diffractometer Bruker Apex II CCD 
Radiation source IMuS micro-focus, Cu 
Theta range for data 
collection 3.85 to 68.30° 
Index ranges -7<=h<=7, -7<=k<=8, -14<=l<=14 
Reflections collected 8782 
Independent reflections 1955 [R(int) = 0.0429] 
Coverage of independent 
reflections 97.7% 
Absorption correction multi-scan 
Max. and min. transmission 0.9870 and 0.6820 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2014/6 (Sheldrick, 2014) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 1955 / 0 / 195 
Goodness-of-fit on F2 1.479 
Δ/σmax 0.001 
Final R indices 1761 data; 
I>2σ(I) 
R1 = 0.0424, wR2 = 
0.1274 
 all data 
R1 = 0.0468, wR2 = 
0.1306 
Weighting scheme w=1/[σ
2(Fo2)+(0.0680P)2] 
where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.283 and -0.451 eÅ-3 
R.M.S. deviation from mean 0.075 eÅ-3 
 
Table 12. Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for 
2-32. 
 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x/a y/b z/c U(eq) 
S1 0.68246(8) 0.20728(7) 0.57834(4) 0.0287(2) 
C1 0.4811(3) 0.3040(3) 0.68347(18) 0.0257(5) 
N1 0.1143(3) 0.4623(2) 0.82919(15) 0.0299(4) 
O1 0.2640(3) 0.4168(2) 0.98717(14) 0.0385(4) 
C2 0.4866(3) 0.3262(3) 0.80546(19) 0.0272(5) 
N2 0.6501(3) 0.2810(3) 0.84828(17) 0.0348(5) 
O2 0.9599(2) 0.5162(2) 0.67332(14) 0.0368(4) 
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 x/a y/b z/c U(eq) 
C3 0.2793(3) 0.4055(3) 0.88206(18) 0.0276(5) 
C4 0.1132(3) 0.4522(3) 0.71031(19) 0.0272(5) 
C5 0.3047(3) 0.3598(3) 0.63786(18) 0.0249(5) 
C6 0.3305(3) 0.3230(3) 0.51801(18) 0.0254(5) 
C7 0.5295(3) 0.2380(3) 0.47253(18) 0.0251(4) 
C8 0.6133(3) 0.1783(3) 0.35150(17) 0.0262(5) 
C9 0.4862(4) 0.2040(3) 0.26786(19) 0.0320(5) 
C10 0.5611(4) 0.1460(3) 0.1547(2) 0.0372(5) 
C11 0.7650(4) 0.0618(3) 0.1213(2) 0.0403(6) 
C12 0.8937(4) 0.0362(3) 0.2031(2) 0.0404(6) 
C13 0.8189(4) 0.0937(3) 0.3166(2) 0.0328(5) 
 
Table 13. Bond lengths (Å) for 2-32. 
 
S1-C1 1.709(2) S1-C7 1.730(2) 
C1-C5 1.377(3) C1-C2 1.448(3) 
N1-C3 1.365(3) N1-C4 1.396(3) 
N1-H1N 0.93(3) O1-C3 1.218(3) 
C2-N2 1.270(3) C2-C3 1.522(3) 
N2-H2N 0.83(4) O2-C4 1.211(3) 
C4-C5 1.466(3) C5-C6 1.407(3) 
C6-C7 1.381(3) C6-H6 0.88(3) 
C7-C8 1.470(3) C8-C13 1.396(3) 
C8-C9 1.397(3) C9-C10 1.376(3) 
C9-H9 0.98(3) C10-C11 1.384(3) 
C10-H10 0.95(3) C11-C12 1.386(4) 
C11-H11 0.98(3) C12-C13 1.379(3) 
C12-H12 1.01(3) C13-H13 0.93(3) 
 
Table 14. Bond angles (°) for 2-32. 
 
C1-S1-C7 92.09(10) C5-C1-C2 122.5(2) 
C5-C1-S1 111.09(16) C2-C1-S1 126.37(17) 
C3-N1-C4 126.54(19) C3-N1-H1N 119.9(16) 
C4-N1-H1N 113.4(17) N2-C2-C1 123.4(2) 
N2-C2-C3 121.0(2) C1-C2-C3 115.54(18) 
C2-N2-H2N 108.(2) O1-C3-N1 121.9(2) 
O1-C3-C2 120.18(19) N1-C3-C2 117.96(18) 
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O2-C4-N1 120.11(19) O2-C4-C5 124.23(19) 
N1-C4-C5 115.65(18) C1-C5-C6 113.66(19) 
C1-C5-C4 121.34(19) C6-C5-C4 124.98(18) 
C7-C6-C5 111.96(19) C7-C6-H6 120.6(18) 
C5-C6-H6 127.5(18) C6-C7-C8 127.46(19) 
C6-C7-S1 111.19(16) C8-C7-S1 121.35(16) 
C13-C8-C9 118.0(2) C13-C8-C7 121.7(2) 
C9-C8-C7 120.20(19) C10-C9-C8 120.9(2) 
C10-C9-H9 117.3(17) C8-C9-H9 121.6(17) 
C9-C10-C11 120.5(2) C9-C10-H10 120.(2) 
C11-C10-H10 119.(2) C10-C11-C12 119.3(2) 
C10-C11-H11 117.5(18) C12-C11-H11 123.1(18) 
C13-C12-C11 120.3(2) C13-C12-H12 118.7(18) 
C11-C12-H12 120.9(18) C12-C13-C8 120.9(2) 
C12-C13-H13 121.(2) C8-C13-H13 118.(2) 
 
Table 15. Anisotropic atomic displacement parameters (Å2) for 2-32. 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k 
a* b* U12 ] 
 
 U11 U22 U33 U23 U13 U12 
S1 0.0250(3) 0.0355(4) 0.0244(3) -0.0055(2) -0.0041(2) 0.0035(2) 
C1 0.0247(10) 0.0273(11) 0.0248(11) -0.0032(7) -0.0039(8) -0.0019(8) 
N1 0.0229(9) 0.0411(11) 0.0243(9) -0.0078(7) -0.0031(8) 0.0023(7) 
O1 0.0336(9) 0.0575(11) 0.0230(8) -0.0079(7) -0.0052(7) 0.0025(7) 
C2 0.0248(10) 0.0289(11) 0.0270(11) -0.0031(8) -0.0032(9) -0.0021(8) 
N2 0.0293(10) 0.0501(12) 0.0252(10) -0.0043(8) -0.0080(8) 0.0023(8) 
O2 0.0261(8) 0.0541(11) 0.0296(9) -0.0042(7) -0.0089(7) 0.0075(7) 
C3 0.0260(11) 0.0319(11) 0.0245(11) -0.0039(8) -0.0036(9) -0.0028(8) 
C4 0.0255(10) 0.0312(12) 0.0248(10) -0.0051(8) -0.0044(9) -0.0029(8) 
C5 0.0245(10) 0.0243(11) 0.0254(10) -0.0023(8) -0.0033(8) -0.0024(8) 
C6 0.0267(10) 0.0261(11) 0.0238(10) -0.0015(8) -0.0060(9) -0.0024(8) 
C7 0.0280(10) 0.0234(10) 0.0231(10) -0.0025(7) -0.0031(8) -0.0025(7) 
C8 0.0282(11) 0.0254(11) 0.0237(11) -0.0008(8) -0.0019(9) -0.0022(8) 
C9 0.0309(11) 0.0393(13) 0.0241(11) -0.0039(9) -0.0034(9) 0.0012(9) 
C10 0.0420(13) 0.0442(14) 0.0249(12) -0.0019(9) -0.0067(10) -0.0008(10) 
C11 0.0443(13) 0.0469(14) 0.0249(11) -0.0072(9) 0.0028(10) 0.0007(10) 
C12 0.0358(13) 0.0472(15) 0.0323(12) -0.0074(10) 0.0039(10) 0.0054(10) 
C13 0.0306(11) 0.0356(12) 0.0303(12) -0.0036(9) -0.0047(10) 0.0040(9) 
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Table 16. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for 
2-32. 
 x/a y/b z/c U(eq) 
H1N -0.017(5) 0.503(3) 0.874(3) 0.042(7) 
H2N 0.622(5) 0.311(4) 0.918(3) 0.062(10) 
H6 0.237(4) 0.348(3) 0.473(2) 0.035(7) 
H9 0.338(5) 0.255(4) 0.288(2) 0.045(8) 
H10 0.473(5) 0.164(4) 0.099(3) 0.067(10) 
H11 0.812(5) 0.025(4) 0.040(3) 0.056(8) 
H12 1.046(5) -0.016(4) 0.180(3) 0.051(8) 
H13 0.903(5) 0.076(4) 0.372(3) 0.061(9) 
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